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9ABSTRACT
Kidney transplantation (Tx) is the treatment of choice for end stage 
renal disease. Immunosuppressive medications are given to prevent 
immunological rejection of the transplant. However, immunosuppressive 
drugs increase e.g. the risk of infection, cancer or nephrotoxicity. A 
major genetic contributors to immunological acceptance of the graft 
are human leukocyte antigen (HLA) genes. Also other non-HLA gene 
polymorphisms may predict the future risk of complications before Tx, 
possibly enabling individualised immunotherapy. 
Graft function after Tx is monitored using non-specifi c clinical 
symptoms e.g. fever and swelling of graft and laboratory markers e.g. 
creatine/cystatin-c measurement. Defi nitive diagnosis of graft rejection, 
however relies on an invasive core needle biopsy of the graft. In acute 
rejection (AR) diagnostics there is a need for an alternative to biopsy 
that would be an easily repeatable and simple method for regular use. 
Frequent surveillance of acute or subclinical rejection (SCR) may improve 
long-term function. This may be especially important in SCR, where by 
defi nition there are no clinical symptoms or indications from laboratory 
tests.
In this thesis associations between cytokine and thrombosis associated 
candidate genes and the outcome of kidney Tx were studied. Cytotoxic 
and co-stimulatory T lymphocyte molecule gene expression biomarkers 
that might be useful for the diagnosis of the clinical and subclinical forms 
of rejection were also investigated. We found that polymorphisms in the 
cytokine genes tumor necrosis factor (TNF) and interleukin 10 (IL10) of 
the recipients were associated with AR. However, the TNF association 
was not observed in a further study implying infl ated odds ratios and p-
values used in the power analysis of the further study based on results 
from fi rst study. A TNF gene polymorphism of the donors was associated 
with delayed graft function. In addition, certain IL10 gene polymorphisms 
of the donors were associated with the incidence of cytomegalovirus 
infection and occurrence of later infection in a subpopulation of recipients. 
Further, polymorphisms in genes related to the risk of thrombosis and 
those of certain cytokines were not associated with the occurrence of 
thrombosis, infarction, AR or graft survival.
In the study of biomarkers for AR, whole blood samples were 
prospectively collected from 50 adult kidney Tx patients. With real-time 
quantitative PCR (RT-QPCR) gene expression quantities of CD154 and 
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ICOS genes differentiated the patients with AR from those without, but 
not from the patients with other causes of graft dysfunction.
Biomarkers for SCR were studied in 31 paediatric kidney 
transplantation patients. We used RT-QPCR to quantify the gene 
expression of immunological candidate genes in a low-density array 
format. In addition, we used RT-QPCR to validate results of the microarray 
analysis. No gene marker differentiated patients with SCR from those 
without SCR. This research demonstrates the lack of robust markers 
among polymorphisms or biomarkers in investigated genes that could 
be included in routine analysis in a clinical laboratory. Even though weak 
associations were found, their predictive value was insuffi cient for use in 
clinical decision-making.
In genetic studies, kidney Tx can be regarded as a complex trait, i.e. 
several environmental and genetic factors may determine its outcome. 
A number of currently unknown genetic factors probably infl uence the 
results of Tx. Added complexity for assessing outcome is provided by 
the interplay of genetic with environmental factors.
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INTRODUCTION
The human kidneys are two bean-shaped organs situated retroperitoneally 
one on each side of the backbone. Each kidney consists of one to two 
million nephrons. A nephron has a complex structure consisting of a 
glomerulus, a Bowman’s capsule, a proximal convoluted tubule, a loop 
of Henle, a distal convoluted tubule and a collecting tubule. The nephron 
fi ltrates surplus or waste molecules and ions from the blood to urine 
and returns useful materials back to circulation. In this manner the 
kidneys maintain body homeostasis. The human kidney also secretes 
two hormones, erythropoietin and calcitriol, and the enzyme renin which 
contribute to regulation of red cell development, calcium metabolism 
and blood volume or blood pressure (http://users.rcn.com/jkimball.
ma.ultranet/BiologyPages/K/Kidney.html).
The deterioration of kidney function leads to disturbance of acid-
base and water-solute balance and accumulation of end products of 
the nitrogen metabolism. Clinical symptoms of malfunction may be e.g. 
urinary retention, elevated blood pressure or fever. Laboratory markers 
may be e.g. high creatine quantities and protein in urine. Cardio-vascular 
diseases and diabetes among others expose to kidney diseases 1.
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REVIEW OF THE LITERATURE
1 KIDNEY TRANSPLANTATION
1.1  General aspects of kidney transplantation
Kidney Tx is the treatment of choice for end stage renal disease (ESRD). 
Studies comparing the quality of patients’ life before and after kidney 
Tx have showed a better quality of life after Tx 2. Even though dialysis 
is a treatment for terminal kidney dysfunction, it results in inferior life 
expectancy. It is also more expensive to society than kidney Tx 3.
The fi rst successful kidney Tx was performed in 1954 between 
English living identical twins 4. In the 1960s, the invention of the fi rst 
immunosuppressive medications, azathioprine and steroids, enabled 
allotransplantation between unrelated individuals. The fi rst kidney Tx in 
Finland took place in 1964 5,6. Txs in Finland are performed at Helsinki 
University hospital with separate Tx units for adults (Kidney Transplant 
Unit, Department of Surgery) and children (Pediatric Nephrology and 
Transplantation, Hospital for Children and Adolescents). This has 
facilitated the adaptation of uniform treatment protocols and follow-
ups of patients in a network of university clinics as well as regional and 
local hospitals 7. Graft and patient survivals have improved with the 
introduction of new immunosuppressants, in particular cyclosporine at 
the end of the 1970s, and tacrolimus and mycophenolate mofetil in the 
1990s 8. In addition, various induction antibodies against lymphocyte 
subpopulations have augmented the treatment repertoire 9. Further, 
novel immunosuppressants and antibodies are under development with 
several currently undergoing clinical trials 10,11.
Graft and patient survivals in kidney Tx worldwide vary considerably 
according to the treatment protocol, donor source and ethnicity. The 
American organisation collecting Tx statistics (ustransplant.org) gives 
1-year graft and patient survival rates for adult patients with a fi rst 
transplant between 2003 and 2004 of 89.5% and 94.7%, respectively. 
The European registry, the Collaborative Transplant Study (ctstransplant.
org), in turn gives 91% and 95.5% 1-year graft and patient survival rates, 
respectively, for adult patients transplanted for the fi rst time between 
2003 and 2005. Graft half-life was 7.8 years in the USA for the era 1988 
- 1996 and 14.2 years in Europe for the era 1985 to 2005 implying that 
half-life has increased during recent years 12 (ctstransplant.org).
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The need for kidney Tx may arise from renal failure due to e.g. chronic 
or acute conditions like trauma, infection or drug toxicity. Chronic renal 
diseases include primary kidney diseases and certain autoimmune 
diseases, and may be secondary to the failure of another organ. Currently, 
the disease most likely to lead to kidney Tx in Finland is diabetes, with 
type 1 diabetes (T1D) being more often the problem than type 2 diabetes 
(T2D) as T2D patients are more often unfi t for Tx. The second most 
common group of diseases are the glomerulonephropathies (excluding 
IgA nephropathy and focal segmental glomerulosclerosis), followed by 
polycystic kidneys. Other causes of uraemia include tubulointerstitial 
and dysplastic diseases 9. A special feature of paediatric kidney Tx 
in Finland is the large number of patients transplanted because of 
congenital nephrotic syndrome of the Finnish type (CNF, NPHS1), a 
rare autosomal recessive disease presenting with massive proteinuria 
at birth 13,14. The disease is responsible for approximately 50% of Tx in 
children.
1.2    Genetic aspects of end stage renal disease
Some of the kidney diseases leading to ESRD are Mendelian disorders, 
e.g. NPHS1, polycystic kidney disease 1 to 3, X-linked Alport syndrome, 
Wilm’s tumor, and familial Mediterranean fever diseases (OMIM - Online 
Mendelian Inheritance in Man www.ncbi.nlm.nih.gov/entrez/query.
fcgi?db=OMIM). However, most of the diseases leading to ESRD are 
genetically complex and even heterogeneous, and hence their more 
detailed genetic dissection is still underway 15-18. As diabetic nephropathy 
(DN) has attracted more studies than any other ESRD, DN genetics is 
briefl y reviewed next.
DN accounts for 40% of ESRD in the Western world. Familial clustering 
of DN and ethnical variation have been observed, both in T1D and T2D, 
indicating genetic factors in the development of the disease. A large 
study on nearly 26000 incident US dialysis patients from more than 450 
dialysis clinics has analyzed the family history of ESRD 19. Independent 
risk factors for a family history of ESRD in fi rst- or second degree relatives 
included earlier age at ESRD onset, female gender, black ethnicity, and 
diabetes-associated nephropathy.
Molecular genetic studies published on DN involve family-based linkage 
and association studies or association analysis in a case-control study 
design. Linkage studies on families have either analyzed a restricted 
chromosomal region using a few polymorphic microsatellite markers 20 
or the whole genome using at least 900 microsatellite markers relatively 
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uniformly distributed throughout the genome 21. SNPs are commonly 
used in association analysis nowadays.
Genome-wide linkage studies on sibling pairs have identifi ed several 
chromosomal regions that may harbour susceptibility genes/variants for 
DN. Chromosome 3q13-q25 has been indicated in DN in T2D African 
Americans 22 and in T1D DN in Caucasian families 20,21, and it has been 
reported that adiponectin gene on 3q is a likely susceptibility gene for DN 
in French and Danish families 23. A large region on chromosome 7q has 
been indicated in DN, predominantly in T2D, in several populations of 
different ethnic origin. Chromosome 18q22-q23 region has also evolved 
in T2D DN in several reports on populations of different ethnic origin 
22,24,25.
Some candidate genes studied code components of the renin-angiotensin 
system, e.g. angiotensin I converting enzyme 2 26, lipid metabolism, e.g. 
apolipoprotein E 27, and membrane proteins such as xylosyltransferase I 
28, nitric oxide synthase 3 29, and superoxide dismutase 2 30,31. Currently, 
at least one genome wide association (GWA) study “Genetics of Kidneys 
in Diabetes (GoKinD)” (search at www.jdrf.org) is being conducted. New 
genetic factors in DN may open the path to new molecular targets for 
drug development and more accurate diagnosis of DN, ultimately perhaps 
reducing the incidence of DN leading to ESRD 32.
1.3  Human leukocyte antigen
1.3.1 Basic features of human leukocyte antigen 
biology
1.3.1.1 Immunogenetics of the human leukocyte antigen system
The major histocompatibility complex (MHC) in the human race is HLA. 
The HLA complex on chromosome 6p21.3 contains more than 200 genes, 
of which more than 40 encode the HLA antigens (Fig. 1). In fact, all the 
known HLA genes are located within the MHC. The remaining 150 genes 
or so in the MHC are not evolutionarily related to the HLA genes, although 
some are involved in HLA function, in particular to the processing of the 
peptide antigens, while some others have immunological functions, e.g. 
related to complement activation. Finally, many appear not to be related 
to the immune response at all 33.
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Figure 1. Location and Organization of the HLA Complex on Chromosome 6. BF 
denotes complement factor B; C2 complement component 2; C21B cytochrome 
P-450, subfamily XXI; C4A and C4B are complement components 4A and 
4B, respectively; HFE hemochromatosis; HSP heat-shock protein; LMP large 
multifunctional protease; LTA and LTB lymphotoxins A and B, respectively; MICA and 
MICB major-histocompatibility-complex class I chain genes A and B, respectively; 
P450 cytochrome P-450; PSMB8 and PSMB9 proteasome ß 8 and 9, respectively; 
TAP1 and TAP2 transporter associated with antigen processing 1 and 2, respectively; 
TAPBP TAP-binding protein (tapasin); TNF-α tumor necrosis factor; and HSPA1A, 
HSPA1B, and HSPA1L heat-shock protein 1A A-type, heat-shock protein 1A B-type, 
and heat-shock protein 1A–like, respectively. Copyright © 2000 Massachusetts 
Medical Society. All rights reserved 34.
The HLA genes are often divided into two major classes. Class I includes 
in particular the classical Tx antigens HLA A, B and Cw, and class II the 
HLA DR, DQ and DP. These molecules are functionally and structurally 
similar (Fig. 2), although they do have certain important differences. 
Class III is a heterogeneous collection of genes where a few families 
dominate. These include genes of the immunoglobulin superfamily 
members as well as those involved in the activation cascades of the 
complement system, hormonal synthesis, infl ammation and cell stress, 
and extracellular matrix organisation. The most of the remaining loci 
are mainly involved in more basic biological functions with no immediate 
connection in the immune system 35.
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Figure 2. Structure of HLA Class I and II Molecules. β2m denotes beta2-microglobulin, 
TM transmembrane region. Copyright © 2000 Massachusetts Medical Society. All 
rights reserved 34.
The α chains of the HLA class I molecules are encoded by the HLA linked 
genes, whereas the β chain is encoded by the β2-microglobulin gene 
located on chromosome 15q21-q22. The α chains have fi ve functional 
domains: two domains (α1 and α2) together form the functionally 
crucial peptide binding groove, an immunoglobulin-like domain (α3), 
the transmembrane region, and the cytoplasmic tail (Fig. 2).
The class II molecules are also formed of two chains, but here both 
chains (α and β) are encoded by genes located in the HLA class II region. 
Each of them has four domains, which are similar to those of class I, 
except that there is only one peptide-binding domain in each chain (α1 
or β1); however, these two domains form a similar type of functionally 
important peptide binding groove (Fig. 2).
The HLA genes show the highest known quantity of classical, allelic 
genetic variation. The most polymorphic ones are HLA-A with over 500 
alleles, HLA-B with over 800 alleles, HLA-C with over 300 alleles, and 
HLA-DRB1 with over 500 alleles (www.ebi.ac.uk/imgt/hla/stats.html). 
There is also strong linkage disequilibrium (LD) between the HLA genes, 
in particular between the B and Cw alleles, and DRB1 and DQB1 alleles 
36,37. In other words, certain allelic combinations appear together more 
frequently than expected from their individual frequencies. Extended 
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haplotypes in the HLA region are conserved in many populations, e.g. 
haplotype HLA-A1-B8-DR3-DQ2 is very common in many Northern 
European populations 38,39. It is currently not established whether the LD 
results from some evolutionary advantage of certain allelic combination, 
recent population mixings, or missing recombination sites in some 
haplotypes.
Most human cells express the HLA A and B, and apparently HLA Cw, 
molecules, but their relative quantities vary between tissues. Only specifi c 
immune cells like B cells, activated T cells, macrophages, dendritic cells, 
and thymic epithelial cells express HLA class II molecules. However, 
interferon gamma (IFNG) can induce other types of cells to express the 
HLA class II genes. Basically, the HLA class I and II molecules share the 
same function: to present peptides to T lymphocytes. This presentation 
is an essential requirement for the activation of the adaptive immune 
response 34.
1.3.1.2 Antigen processing and presentation
A special molecule, ubiquitin, marks intracellular proteins that are 
no more needed for disassembly. Chaperones make marked proteins 
available to a proteasome degradation process where they are digested 
into peptides of variable length. Peptides are also produced in endocytic 
vesicles where extracellular proteins are digested by lysosomes and 
proteolytic enzymes 40.
In addition to foreign proteins, the proteasomes also digest self-
proteins, the resulting peptides being picked up by transporters 
associated with antigen processing (TAPs). TAP1 and TAP2 genes encode 
TAP proteins. TAPs form channels through the endoplasmic reticulum 
(ER) and peptides move via these and bind to class I molecules. The 
class I molecules have been assembled from α chains and β2m in ER 
with the help of chaperones like TAP-binding protein (TAPBP) and others. 
After binding to the suitable peptide, the class I molecule moves to the 
cell surface where it is displayed 41.
Class II molecules are manufactured in the same way as class I 
molecules up until the class II molecule peptide binding in cytoplasm. 
Before peptide binding, the invariant chain binds to the peptide-
binding groove. In the cytoplasm the class II molecules intersect with 
endosomes. Proteasomes, with the help of the HLA-DM molecule, cut 
the invariant chain and exogenous peptide binds to the groove. This 
complex is exported to the surface of the cell 42.
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In general, the class I molecules present peptides from endogenous 
sources and class II molecules from exogenous sources. On an 
uninfected cell surface, the HLA molecules bind hundreds of thousands 
of self-peptides. Antigen-presenting cells (APCs) express HLA-peptide 
complexes, which T-cells bind and recognize as self or non-self in a 
process described in the following sections 34.
1.3.1.3 Human leukocyte antigen and T cell selection
T cells mature in thymus from lymphocyte progenitors. Immature double-
positive T cells interact with their T cell receptor (TCR), as well as CD4 
and CD8 coreceptors to HLA molecules. In the selection process if TCR 
binds to HLA class I, the T cell starts to down-regulate CD4 receptors 
and up-regulate CD8 receptors, and if TCR binds to HLA class II, the T 
cell starts to down-regulate CD8 and up-regulate CD4 43,44 (Fig. 3).
Figure 3. Mature CD4 and CD8 positive T cells make contact with TCR and CD4 or 
CD8 molecules to an APCs HLA class II and class I molecules representing peptide, 
respectively. TCR denotes T cell receptor; HLA human leukocyte antigen; APC antigen 
presenting cell.
During T cell maturation in the thymic cortex T cells encounter HLA 
molecules. T cells that are unable to recognize the self-HLA molecules 
will die by apoptosis. In the thymic medulla, T cells with strong binding 
to self-peptides presenting HLA molecules undergo apoptosis. On the 
periphery, T cell binding to HLA class I molecules with a recognized ligand 
leads to T cell maturation to a CD8 cytotoxic killer T cell while binding 
to HLA class II molecules results in maturation to a CD4 helper T cell. 
Maturation activates T cells to produce INFG and other cytokines, and 
these cytokines enhance immune response by increasing the expression 
of HLA class I and II molecules 45.
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1.3.1.4 Interaction between specifi c human leukocyte antigen 
molecules and peptides
Only a few amino acids of each peptide bind directly to the peptide 
binding groove of HLA. These interactions have been described in detail 
by crystallographic studies 46,47. One HLA allele has the ability to bind 
many different peptides if they all share certain critical amino acids at 
particular positions, that is, they fulfi l the criteria for the peptide binding 
motif. The amino acids that form the critical pockets of the peptide 
binding groove and thus determine the peptides able to bind therein, 
show a high quantity of genetic variation between HLA alleles. Hence, 
different HLA alleles bind and present to the immune response different 
sets of peptides. Although the peptide binding motif gives the general 
outline of peptides bound by each of the HLA alleles, the requirements 
are not absolute. One HLA allele can therefore bind thousands of different 
peptides 48 (Fig. 4).
Figure 4. A TCR recognized HLA-peptide complex. TCR denotes T cell receptor, HLA 
human leukocyte antigen.
HLA is currently the most important known genetic factor infl uencing 
the outcome of kidney Tx. In the next sections, aspects of HLA biology 
and matching in kidney Tx are covered.
1.3.2 Clinical histocompatibility and human leukocyte 
antigen matching
Successful kidney Tx requires, in addition to special surgical skills, careful 
immunogenetic matching between the donor and recipients. In many 
centres worldwide, Tx is only considered if (i) the recipient and donor 
are blood group ABO matched, (ii) the recipient has not developed prior 
antibodies against the donors HLA antigens (a negative cross-match), 
and (iii) there is suffi cient HLA-A, -B and -DR similarity between the 
recipient and the donor 49.
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HLA matching for kidney Txs has two main aims. First, a good 
immunological histocompatibility between the donor and recipient 
diminishes immune activation against the graft. Second, emergence of 
antibodies against foreign HLA antigens of the graft is potentially harmful 
for the long-term graft survival (GS), and their emergence is certainly 
harmful if the recipient undergoes retransplantation. In other words, 
preformed antibodies, or a positive cross-match before Tx, may lead 
to acute or hyperacute rejection and deterioration of the graft. Long-
term humoral immunity against the graft promotes chronic rejection 
and shortened GS 50. The detection of anti-HLA antibodies is discussed 
in the section on methods for AR diagnosis.
Foreign HLA antigens promote cellular immunity. The cellular 
response can be divided into direct allorecognition, primarily by cytotoxic 
CD8 T cells, and indirect allorecognition by effector/helper CD4 T 
lymphocytes.
Worldwide there are several HLA matching protocols for kidney 
Tx. Centres may match for all HLA-A, -B, and -DR antigens, or some 
mismatching in HLA-A, -B, and -DR antigens, and either broad or split 
antigens can be tolerated. There are programs for acceptable and 
unacceptable mismatches for highly sensitized Tx candidates, DR-only 
matching, cross-reacting groups of antigen (CREG) matching, structurally 
based matching, amino acid residue mismatching, and HLA Matchmaker 
program matching 51. In Finland, an acceptable HLA match involves the 
sharing of at least two ‘broad’ antigens in the HLA-A, and HLA-B genes, 
and one antigen in HLA-DR 6.
Other essential factors affecting the outcome of Tx include the quality 
of the donor kidney, donor age, cold ischemia time, and the experience 
of the Tx team 51. The Collaborative Transplant Study (CTS) reports 
that HLA mismatch worsened GS independently of other known factors 
infl uencing GS (www.ctstransplant.org/). Good HLA matching also 
signifi cantly improves GS in Finnish kidney Tx 52.
1.4  Complications in kidney transplantation
Complications experienced by transplant recipients include AR, delayed 
graft function, cytomegalovirus infection, and/or vascular complications, 
and these are reviewed in the following sections. Other signifi cant 
adverse effects (fi rst year incidences in spesifi c studies in parentheses) 
include BK-virus nephropathy (8% 53) and other microbe infections, 
chronic rejection (4% 54), post-transplant lymphoproliferative disease 
(1% 55) and other cancers, and there are common minor problems, e.g. 
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cosmetic issues and mild gastrointestinal complications. These are not 
reviewed as they are beyond the focus of this thesis.
1.4.1 Acute rejection
Rejection is an immune response to an allogeneic graft. Immunosuppressive 
medication is given to prevent rejection in an alloTx. A kidney Tx patient 
experiencing an AR episode may present with fever, chills, night sweats, 
myalgias, and tenderness over the allograft, oliguria and hypertension. 
Laboratory tests may indicate increased creatinine or a decrease in 
glomerular fi ltration rate. An ultrasound scan may reveal a swollen 
kidney and delayed and decreased blood fl ow, among other functional 
parameters 56. These, with or without biopsy fi ndings, usually lead to 
suspicion of AR. Histology and other tests in use and in development are 
reviewed in the section 1.6. AR is treated with steroids, or in steroid-
resistant rejection with antibodies to T cells, among others. Rejection 
episode length and response to therapy determine the resulting graft 
damage, which may only be partly reversible. Permanent damage may 
lead to long-term deterioration of graft function. It is important to 
recognise patients with high rejection risk and diagnose rejection early 
to limit damage to the graft and improve the Tx prognosis.
Most AR episodes occur in the fi rst three months after Tx. AR occurring 
later is often suspected to be related to non-compliance. However, 
the incidence of AR has decreased with the evolution of medical care. 
This has made studies in cohorts diffi cult, because the incidence of 
AR is often as low as 10 to 15%. According to ustransplant.org, the 
incidence of AR has continually decreased from 1996 through 2004, 
with respective annual incidences of 51%, 29%, 21%, 19%, 17%, 17%, 
15%, 13% and 11%. However, long-term GS for the patients with AR 
has not increased 57. Future studies should probably use other endpoints 
to predict outcome, such as serum creatinine or glomerular fi ltration 
rates. In addition, the decreasing AR incidence has improved short-
term, but not long-term, allograft survival. Factors associated with late 
allograft loss, such as calcineurin inhibitor toxicity, chronic rejection, 
and BK virus nephropathy, may provide better predictors of long-term 
allograft loss than AR 58.
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1.4.1.1 Immune systems involved in rejection
AR results from the innate and acquired allogeneic responses to 
transplanted graft. These responses follow each other in sequence, in three 
processes: 1) naïve host T cells recognise alloantigens, 2) alloreactive 
T cells are activated and expand, 3) target cell destruction takes place 
in an effector phase (Fig. 5) 59. Alloantigens can be divided into two 
Figure 5. Effector mechanisms responsible for the rejection of combined class I and 
class II MHC-mismatched allografts. In the direct pathway, host CD4 T cells recognize 
intact MHC molecules on donor dendritic cell (DC) (stained red). In the indirect 
pathway, recipient DC (stained blue) engulf and process donor MHC molecules before 
donor MHC molecules present themselves as MHC-derived allopeptides to host CD4 
T cells. CD8 T cells that recognize donor MHC class I molecules will receive help from 
activated alloreactive CD4 T cells. The effector phase of rejection (depicted around 
a tubule within a kidney graft) involves: (a) CD8 and CD4 T cell cytotoxicity with 
the perforin/granzyme and Fas/FasL pathway, respectively; (b) CD4 and CD8 derived 
IFNG production and delayed-type hypersensitivity, where macrophages release toxic 
molecules, such as NO, TNF, and oxygen species; (c) antibodies reactive to donor 
MHC molecules, which will mediate complement activation or antibody-dependent 
cell-mediated cytotoxicity. The cells and pathways not involved in rejection are shown 
in grey. Copyright © 2002 Lippincott Williams & Wilkins. All rights reserved 59.
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classes: foreign MHC and minor alloantigens. The above discussed HLA 
matching attempts to lessen the MHC differences between the donor 
and recipient 60. Even though full HLA matching were to be achieved 
e.g. in sibling Tx, minor alloantigen allopeptides would still result in a 
degree of immunoactivation as they are presented by shared donor and 
recipient MHC molecules 61. Allopeptides derive from differences between 
donor and recipient proteins, e.g. male antigen in sex-mismatched Tx 
or proteins having amino-acid differences, or di-allelic polymorphisms in 
coding or controlling sequences 62,63.
1.4.1.2 Allorecognition
In direct allorecognition the TCR on CD8 T cells of the recipient 
recognize the donor’s foreign HLA class I molecules directly on the cell 
surface. The recognition takes place in lymph nodes and spleen, where 
naïve alloreactive T cells contact donor APCs. Transplantation surgery 
is associated with ischemia/reperfusion injury which activates donor 
APCs to migrate from allograft to recipient lymphoid tissues 64. In the 
indirect allorecognition recipient APC cells engulf donor HLA I and II 
molecules, digest them into peptides and present them via recipient 
HLA II molecules to the recipient’s CD40 T lymphocytes. Recipient DCs 
circulate to the transplanted graft attracted by the chemokines and 
increased graft endothelial cell adhesion molecule expression. Recipient 
DCs circulate back to spleen and lymph nodes to prime naïve T cells 65. 
In addition to the signal from the HLA–TCR complex, other co-signals are 
needed for the immune activation, in particular co-stimulatory molecules 
e.g. in DCs B7, CD40 and OX40 ligand and their receptors, and in T cells 
CD28, CTLA4, CD40LG (CD154) and OX40. Binding of these molecules 
triggers intracellular pathways involving IL2 secretion and activation of 
transcription factors such as NFKB, which activates genes expressing 
chemokines and cytokines 66.
CD4 T cells secrete cytokines according to their differentiation into 
Th1 and Th2 cells. The major cytokines of Th1 cells are IFNG and IL2, 
which activate CD8 T cells and themselves by the expression of Fas 
ligand (FASLG) to cytotoxicity. Th2 cells mainly secrete IL4, IL5, IL9, 
IL10 and IL13, which activate eosinophils 67.
Alloreactive T cell cytotoxicity is mainly mediated by perforin/
granzyme and the Fas/FASLG system, leading to target cell apoptosis 68. 
In the tight junction between cells, CTL makes contact with donor MHC 
molecule and cytotoxic granules fuse to the target membrane. Granule 
molecules trigger caspase production, which leads to apoptosis 69.
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B cells produce alloantibodies, which internalize foreign HLA molecules 
bound by their immunoglobulin (Ig). Foreign HLA molecules are cleaved 
into peptides which are presented by B cells’ own MHC class II molecules 
to CD4 T cells in order to obtain signals enhancing B cell alloantibody 
production 70. Alloantibodies binding to cells of the graft may activate the 
complement system, and subsequently graft-infi ltrating immune cells 
like macrophages, neutrophils and eosinophils 71. In addition, natural 
killer (NK) cell binding to Ig molecules initiates perforin/granzyme-
mediated NK cytotoxicity, otherwise specifi ed as antibody-dependent 
cell cytotoxicity (ADCC) 72.
Th1 cell mediated delayed-type hypersensitivity (DTH) appears 
as tissue swelling and induration, where T cells, macrophages and 
neutrophils induce vascular permeability and infl ammatory infi ltrate. 
Antigen-specifi c Th1 cells release IFNG and TNF, which trigger the 
macrophage production of nitric oxide (NO) and oxygen intermediates. 
NO elicits cytotoxicity, vasodilation and edema. TNF induces apoptosis 
and necrosis through caspase activation. These activations lead to DTH 
mediated allograft rejection 73.
1.4.1.3 Tolerance
The ultimate aim in the prevention of AR with immunosuppression is 
to induce immunological tolerance between the recipient and graft. 
Tolerance induction is complex. It can be relatively easily induced in 
mouse, rat, pig and primate models of transplantation e.g. by blockade 
of immunological co-signals 74. However, in clinical transplantation 
tolerance induction remains an elusive goal that seems impossible to 
reach with current immunosuppressive protocols. The use of cyclosporine 
may lead to either benefi cial or adverse interaction depending on the 
balance between the effi cacy of the co-stimulatory signal blockade and 
the stringency of the alloimmune response 75. Tolerance induction is 
currently one of the main goals in transplantation research 76,77.
1.4.2 Delayed graft function
The recipient usually starts secreting urine within the fi rst day after 
kidney Tx and will no longer need dialysis. If not, the situation is called 
DGF. DGF is not a well-defi ned entity but is usually a centre dependent 
defi nition. The defi nition for DGF in Finland is from Halloran et al. 78, i.e. 
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plasma creatinine concentration higher than 500 μmol/L throughout the 
fi rst post-transplant week, or need for more than one dialysis session in 
the fi rst week, or oliguria <1L/24hr lasting more than two days 79. The 
incidence of DGF varies with different factors in the donor and recipient, 
and in the transplant procedure 80. Major factors predisposing to DGF 
are long cold ischemia time (CIT), high donor age, female kidney to 
male recipient, and high creatinine quantities in the donor 81. GS is 
reported to be approximately 10% lower with DGF 82. This fact has led 
to efforts to shorten CIT and to fi nd novel drugs for diminishing the 
ischemia-reperfusion injury 83,84.
1.4.3 Cytomegalovirus infection
Cytomegalovirus (CMV) is a betaherpesvirus with linear double-stranded 
DNA genome. CMV infection is usually mild and subclinical, and stays 
as latent after infection. However, immunosuppressive medication 
predisposes to infections and re-activation of microbes and viruses. CMV 
infection occurs in 25 - 60 % of kidney graft recipients, depending on 
the serological status of the recipient and donor, and on prophylactic 
treatment. CMV serologically negative recipients (R-) who receive a 
serologically positive donor (D+) organ have the highest risk. These 
recipients often receive prophylaxis 3 - 6 months post-Tx 85,86. New 
antiviral prophylactic treatments have reduced the risk for CMV infection 
considerably. CMV infection is commonly diagnosed using antigenaemia 
test or PCR. CMV prophylaxis reduces the one-year post-Tx incidence of 
AR in R-/D+ groups from 32.4% to 26.3% 86. CMV disease during the 
fi rst 100 days after Tx is associated with 71% GS, compared to 86% GS 
without CMV 87.
1.4.4 Vascular complications
Kidney Tx involves suture and catheterization of veins and urinary 
bladder. These procedures increase the risk of thrombosis (the formation, 
development or presence of a blood clot) immediately after operation. 
Recipient factors such as age, immobility, and primary disease infl uence 
the long-term risk of thrombosis and infarction. Recipient death 
with a functioning graft is mainly due to vascular complications, e.g. 
myocardial and cerebral infarctions 88-91. Vascular AR may also promote 
microvascular thromboses, which may lead to graft loss 92. In addition, 
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renal artery- or vein thrombosis due to surgical complications or factor 
V Leiden mutation may lead to immediate graft loss 93,94.
1.5 Genes associated with acute rejection, 
delayed graft function, cytomegalovirus
 and vascular complications
Several gene polymorphisms have been studied for their potential to 
predict Tx outcome (reviewed in several articles 95-100). So far, these 
studies have been candidate gene studies on solid organ Tx, although GWA 
studies are underway (reviewed in later section). After the completion of 
human genome sequence 101 the International HapMap consortium has 
made available for everyone studying the human genome over three 
million SNPs validated in several populations 102,103. The HapMap internet 
database includes also the information of LD between SNPs in same 
chromosome (hapmap.org). This LD can be used to choose tag SNPs 
which represent all the SNPs in LD with tag SNP for genotyping entire 
genes. In the HapMap CEU samples represent adequately basis for tag 
SNP selection in Finnish individuals 104. In addition, tag SNPs are used 
among others in the genotyping platforms for GWA studies.
A good genetic association study is designed to include a suffi cient 
number of samples, implemented to collect reliable phenotypic data, 
perform genotyping rigorously, and interpret results correctly 105. Solid 
organ Tx candidate gene studies are founded on the immunological basis 
of Tx. Cytokines, chemokines, the receptors of mononuclear blood cells 
and other related genes have been screened for possible genetic variations 
associated with the outcome. The results from these studies have been 
mostly contradictory or non-conclusive due to their small size. The small 
patient number in these genetic studies has led to various problems, 
including sensitivity to variability in the patient and donor characteristics, 
and analysis methods. In addition, the non-consistent nomenclature of gene 
polymorphisms makes the comparison of studies diffi cult. The refSNP (rs) 
numbers, the standard nomenclature for gene polymorphisms from the 
database of single nucleotide polymorphisms (dbSNP), or Human genome 
variation society (HGVS) mutation nomenclature recommendations are 
not commonly used. Currently there is not a single gene outside the HLA 
and ABO blood groups that is commonly accepted to be of importance 
in kidney Tx 106. However, comprehensive prospective studies are yet to 
come.
Genetic epidemiology is a term that indicates a combination of the old 
formal epidemiology (variables changing during an individual person’s 
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life-time) and new emerging genetic variation typing and analysis 
methods (variables not changing during an individual person’s life-
time). Traditional epidemiology follows strict guidelines when reporting 
associations between environmental factors and outcomes, e.g. diseases. 
However, even with extremely detailed studies not everything can be 
taken into account as a risk factor, or measured variables are confounding, 
intervening, suppressing or interacting without an acknowledgement of 
this. Adding this to the genetic diversity, which is not limited to SNPs, 
several factors can infl uence the outcome 107. Thus, many published 
articles may report false-positive or false-negative results 108.
1.5.1 Cytokine genes
Cytokines can be divided into subgroups of interleukins, interferons and 
miscellaneous hematopoietins. Since the launch of the HapMap project, 
several thousands of gene polymorphisms have been found in genes 
encoding cytokines. Some of these may, or have been shown to, have 
an effect on gene function or its expression quantities where certain 
allele/genotype/haplotype is associated with decreased or increased 
gene expression compared to the other variant. The mechanisms of 
these mediation effects are not usually known 109. The published studies 
still mainly include only a single or a few polymorphisms per cytokine 
gene, and haplotype analyses are rare. All the cytokine genes and 
polymorphisms studied in this thesis are listed in table 1 which also 
denotes the primary source and effect of each cytokine. Relevant studies 
to this thesis are discussed in more detail in Results and Discussion.
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1.5.1.1 Tumor necrosis factor
The most studied cytokine is TNF, mainly known for its devastating 
effects on sepsis leading to massive infl ammatory reactions. TNF causes 
pro-infl ammatory responses in response to several immunological 
challenges. Systemic TNF causes e.g. fever, hypotension, and shock 147. 
TNF is also involved in the AR cascade 148. The TNF gene lies on 6p21.3 
in the region of MHC class III and is in LD with classical HLA genes 149. 
The TNF gene is 2778 bases long and encodes a protein of 233 amino 
acids. The most studied polymorphism in the TNF gene is the G(-308)A 
promoter polymorphism that infl uences the expression of TNF protein 
111. The -308A allele associated with high cytokine expression is found in 
the ancestral HLA-A1-B8-DR3 haplotype which confers susceptibility to 
many autoimmune diseases 150. The G(-308)A polymorphism has been 
found to associate with the outcome of kidney Tx, although results are 
contradictory (Table 1).
1.5.1.2 Transforming growth factor beta 1
Transforming growth factor beta 1 (TGFB1) regulates proliferation and 
differentiation of many cell types. In the immune system TGFB1 affects 
many cell types, e.g. T cell survival, proliferation, Th differentiation 
and effector functions 151. The TGFB1 gene lies in 19q13.2, is 23402 
bases long and encodes a protein of 390 amino acids. In kidney Tx 
TGFB1 is known as fi brogenetic factor, whose increased expression has 
been associated with chronic rejection 152,153. In addition, a signifi cant 
association between TGFB1 gene and graft and patient survival has been 
reported 154. Polymorphisms in the exon 1 of the TGFB1 gene codons 
10T/C and 25C/G have been associated with the outcome of kidney Tx 
in many studies. Again, however, there are also many studies that have 
not found the association (Table 1).
1.5.1.3 Interleukin 10
IL10 promotes the Th2-type immune response leading to antibody 
production. The effects of IL10 are generally thought to be anti-
infl ammatory, and to suppress the Th1-type immune response. The 
IL10 gene lies in 1q32.2, is 4892 bases long and encodes a protein 
of 178 amino acids. There are several polymorphisms in the promoter 
region of IL10. However, the effects of these on IL10 production remain 
30
unclear. The -1082G allele has been associated with a higher expression 
quantity in vitro and in vivo 140. In another study, the -1082A allele was 
reported to confer a two-fold increase in the transcriptional activity of the 
IL10 promoter compared to the G allele 155.
The confl icting results of the in vitro and in vivo studies of the IL10 
polymorphisms are refl ected in the clinical studies of the role of the 
cytokine in the development of AR 140. While IL10 polymorphisms have 
been reported to affect the outcome of kidney Tx in several studies, 
there are many reports that have been unable to detect the infl uence of 
IL10 (Table 1).
1.5.1.4 Interleukin 6
IL6 regulates many aspects of the immune response, e.g. T cell 
differentiation 156. The IL6 quantities increase in the incidence of 
infl ammation, tissue damage, hypoxia, or infection 157. The IL6 gene 
lies in 7p15.3, is 6113 bases long and encodes a protein of 212 amino 
acids. The IL6 promoter haplotype regulates the IL6 mRNA and protein 
quantities 158. The promoter polymorphism G(-174)C, together with 
nearby polymorphisms, have been the subject of several kidney Tx 
studies (Table 1).
1.5.1.5 Interferon gamma
Activated T cells produce IFNG. Mitogens for T cells may mimic this 
induction. IFNG has several properties: it modulates immune activity by 
e.g. activating macrophages; it mediates the lytic effect; it potentiates the 
actions of other interferons; and it inhibits intracellular microorganisms 
other than viruses 159. The IFNG gene lies in 12q15, is 4974 bases long 
and encodes a protein of 166 amino acids long.
IFNG acts both as an anti-rejection and pro-rejection cytokine, e.g. 
by induction of microvascularisation in the grafted organ and increasing 
the expression of MHC. Whether the main effect will be anti- or pro-
rejection depends mainly on the secretion time after kidney Tx, being 
protective early and then later antagonistic 160. The most studied IFNG 
polymorphisms in kidney Tx are intron 1 SNP T(+874)A and CA short 
tandem repeat microsatellite (rs3138557). These have been associated 
with AR, and donor polymorphism to chronic allograft nephropathy 
(Table 1).
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1.5.2 Thrombosis-associated genes
The blood coagulation cascade involves several molecules which lead 
to thrombosis and infarction 161. In addition, in the epithelium of 
rejecting graft blood vessels the coagulation cascade activates forming 
infi ltrates in the infl ammation area. Infi ltrates consist of e.g. platelets, 
neutrophils and monocytes 162. All the thrombosis associated genes and 
polymorphisms studied in this thesis are listed in table 2 where the 
effect of each molecule is also denoted. The relevant studies to this 
thesis are discussed in more detail in Results and Discussion.
1.5.2.1 Coagulation factor V
The F5 gene lies in 1q24.2, is 72422 bases long and encodes a protein 
of 2224 amino acids long. In the context of kidney Tx the factor V Leiden 
mutation (FVL, F5 R506Q, G1691A) is currently the most thoroughly 
investigated polymorphism of the genes of the coagulation cascade. 
The FVL mutation associates with thrombotic events, rejection episodes, 
GS and infarction. Patients with the FVL mutation are often given anti-
thrombotic prophylaxis. However, in some studies investigators have 
been unable to demonstrate any association between the FVL mutation 
and outcome of renal Tx (Table 2). A second F5 mutation (F5R2, H1299R, 
A[R1]4070G[R2]) occurs in the B-domain of the protein that is released 
upon the activation of F5. The H1299R mutation is postulated to lower 
F5 concentrations either by reducing F5 biosynthesis or increasing F5 
molecule turnover 163. The effects of the F5 H1299R mutation on the 
outcome of kidney Tx have not been previously investigated. In the 
general population, the F5 H1299R mutation has been associated with 
increased risks of infarction and thrombosis 164.
1.5.2.2 Coagulation factor II
The coagulation factor II (F2) gene lies in 11p11.2, is 20300 bases long 
and encodes a protein of 622 amino acids long. The F2 mutation G20210A 
changes the F2 pre-mRNA processing. More F2 mRNA is translated to 
the F2 protein, which leads to increased F2 concentrations and elevated 
risk of thromboembolism 165. The G20210A mutation associates with 
decreased GS after kidney Tx (Table 2). However, in other studies the 
results have been confl icting (Table 2).
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1.5.2.3 Methylenetetrahydrofolate reductase
The methylenetetrahydrofolate reductase (MTHFR) gene lies in 1p36.22, 
is 20335 bases long and encodes a protein of 656 amino acids long. An 
MTHFR mutation (A223V, C677T) results in elevated plasma homocysteine 
quantities and higher risk of thrombosis secondary to cytotoxic effects 
on endothelial cells. In kidney Tx, the mutation has been associated 
with AR and the development of chronic allograft nephropathy, but not 
with decreased patient or GS (Table 2).
1.5.2.4 Protein C, tissue factor pathway inhibitor, coagulation 
factor XIII
Protein C (PROC), tissue factor pathway inhibitor (TFPI) and coagulation 
factor XIII (F13A1) are also candidate genes for thrombosis but these 
have not been studied in kidney Tx patients. The PROC gene lies in 
2q14.3, is 10802 bases long and encodes a protein of 461 amino acids 
long. PROC inactivates e.g. factor Va, thereby inhibiting clot formation. 
The PROC W380G, T8853G loss-of-function mutation, which may be 
regarded as a member of the ‘Finnish disease heritage’ 166, results in a 
defi ciency of PROC, and an increased risk of thrombosis. The TFPI gene 
lies in 2q32.1., is 87880 bases long and encodes a protein of 304 amino 
acids long. The pro-thrombotic TFPI mutation (P151L, C536T) is thought 
to increase prothrombinase complex activity and thrombin production 
167. The F13A1 gene lies in 6p25.1, is 176584 bases long and encodes 
a protein of 732 amino acids long. F13A1 mutation (V34L, G103A) is 
associated with protection from thrombosis. The mutated protein has 
a lower ability to catalyze fi brin polymer formation than the wild type 
protein. In a recent meta-analysis of diagnosed thrombosis cases and 
controls in the general population, the V34L mutation had a signifi cant 
protective effect against thrombosis (homozygote odds ratio (OR) 0.63, 
95% confi dence interval (CI) 0.46 - 0.86) 168.
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1.5.3 Other genes studied in renal transplantation
Polymorphisms in other genes such as cytokines LTA, interleukin 
1, interleukin 2, interleukin 4, chemokines like chemokine ligand 5, 
chemokine ligand 12, chemokine receptor 2, chemokine receptor 5, 
melanin concentrating hormone receptor 1, monocyte chemotactic 
protein-1, adhesion molecules like intercellular adhesion molecule 1, 
platelet/endothelial cell adhesion molecule, selectins, costimulatory 
molecules like cytotoxic T-lymphocyte-associated protein 4, CD28 
molecule, renin-angiotensin system molecules like angiotensin I 
converting enzyme 1, angiotensinogen, angiotensin type 1 receptor, 
angiotensin type 2 receptor, cytochrome P450 family 11 subfamily 
B polypeptide 2, and other molecules like growth factors and G 
proteins have also been studied in the kidney Tx setting 99. However, 
these individual reports await confi rmation from replication studies. 
Candidate gene studies may become fewer as they are replaced by 
future GWA studies. The only so far published GWA study from Tx 
patients was a case-control association study using 50,947 gene-
based SNPs to identify genetic variations that might be associated 
with cardiovascular risk factors in 72 renal transplant recipients with 
cyclosporine therapy. The results were used to analyse predictive 
performance of cardiovascular risk factors associated with SNPs 197. 
The Transplant Genomics Collaborative Group is conducting a GWA 
study on kidney Tx recipients and donors (www.genetics.ucla.edu/
transplant-genomics/research/programs/project3.php).
1.6 METHODS AND BIOMARKERS STUDIED BY 
THESE METHODS FOR DIAGNOSING ACUTE 
REJECTION
Biomarkers are variables or predictors of a specifi ed clinical condition 
measured by various laboratory methods. These variables may change 
over time according to the progression of the disease. Biomarkers have 
conventionally been protein molecules measured from bodily fl uids or 
tissue biopsies. Gene expression and cell surface structure profi ling 
using microarray and fl ow cytometry or mass spectrometry are the 
latest methods used 198. In the next sections biomarkers are reviewed 
according to the method used.
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1.6.1 Histology
A radiologist or nephrologist takes the kidney biopsy and a pathologist 
interprets the histologically stained sample and in some cases the 
sample is further stained with specifi c antibodies to molecules 
specifi c for AR subtypes. Histopathological evaluation may allow the 
identifi cation of the cause of acute allograft dysfunction e.g. acute 
tubular injury, calcineurin inhibitor toxicity, obstruction or various 
infl ammatory infi ltrate processes. Standardization of renal allograft 
biopsy interpretation is necessary to guide therapy and to establish an 
objective end point for clinical trials. The fi rst meeting for this purpose 
was in Banff, Canada in 1991, to develop an international classifi cation 
for the histological grading of solid organ transplants. The biennial 
congresses have reported their proceedings in peer reviewed journals 
since the international consensus discussion began at Banff, and the 
process continues via the internet (cybernephrology.ualberta.ca/Banff/). 
In the Banff schema, kidney biopsy fi ndings are rated and categorized 
to assist diagnosis and therapy. Banff 97 classifi cation “defi nes types 
of acute/active rejection. Type I is tubulointerstitial rejection without 
arteritis. Type II is vascular rejection with intimal arteritis, and type III 
is severe rejection with transmural arterial changes. Biopsies with only 
mild infl ammation are graded as borderline/suspicious for rejection. 
Chronic/sclerosing allograft changes are graded based on severity of 
tubular atrophy and interstitial fi brosis. Antibody-mediated rejection, 
hyperacute or accelerated acute in presentation, is also categorized, as 
are other signifi cant allograft fi ndings” 199. Antibody mediated rejection 
in particular is diagnosed using immunostaining of capillaries or arteries 
for C4d 200. Other molecules associating with AR include B7-1, B7-2, 
CD14, CTLA4, allograft infl ammatory factor-1, TNF, IL18 and growth 
arrest-specifi c gene 6 201-205. Moreover, AR does not associate with 
molecules such as CD20, CD40, CD40L, CD25, perforin, TNF and TGFB1 
201-203,206,207. In the future, biopsy sections may be stained with a wider 
repertoire of antibodies to explore the molecular pathway involved in 
the rejection process 208.
The latest Banff classifi cation from 2005 has abandoned the non-
specifi c term chronic allograft nephropathy and recognizes the entity 
of chronic antibody-mediated rejection. Renal biopsies are classifi ed to 
six classes: 1. normal, 2. antibody-mediated rejection, 3. borderline 
changes, 4. T-cell-mediated rejection, 5. interstitial fi brosis and tubular 
atrophy, 6. other changes not considered to be due to acute and/or 
chronic rejection 209.
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In addition, a clinician may take a fi ne needle aspiration biopsy 
(FNAB) 210. The FNAB samples are scored according to a total corrected 
increment (TCI) value which is based on counting immunoblasts, activated 
lymphocytes, plasmablasts and activated monoblasts in the cytological 
samples 211. FNAB can be used as a frequent monitoring of AR in kidney 
graft 212. However, FNAB cannot identify vasculitis and tubulitis, which are 
important components of the Banff grading systems for rejection 213.
1.6.2 Enzyme-linked immunoabsorbent assay
Enzyme-linked immunoabsorbent assay (ELISA) is an immunoassay 
utilizing an antibody labelled with an enzyme marker. The enzyme or 
the antibody is bound to an immunosorbent substrate, and the change 
in enzyme activity from the enzyme-antibody-antigen reaction is 
proportional to the concentration of the antigen and can be measured 
e.g. spectrophotometrically 214. The risk of AR can to some degree be 
estimated by determination of pretransplant anti-HLA antibodies. One of 
the methods used is the ELISA, where solubilized class I or class II HLA 
antigens are fi xed onto microtiter plates. Antibodies against both HLA 
class I and class II increase rejection episodes in HLA mismatched fi rst 
grafts. ELISA assay is perhaps more sensitive for detecting additional 
antibodies with clinical relevance. However, it cannot detect other Tx-
relevant non-HLA antigens or isotype antibodies other than IgG 215.
Another pre-transplant test for predicting rejection is measurement 
of soluble CD30 (sCD30), most often using ELISA. CD30 is preferentially 
expressed on Th2-type T cells with alloimmune responsiveness. Elevated 
quantities of sCD30 are associated with increased risk of AR, independently 
of anti-HLA antibodies or Tx sequence 215. However, in the Finnish Txs, 
the quantities of sCD30 did not predict rejection incidence 216; but on day 
21 posttransplant the rejecting patients had signifi cantly higher relative 
sCD30 quantities than the non-rejecting patients 216. A pilot study 
implied that high sCD30 quantities at post-Tx days 3 to 5 predicted AR 
well 217. In addition, pre- and post-transplant CD40 quantity predicts AR. 
CD40 is expressed in injured kidney and is involved in the extravasation 
of lymphocytes at sites of infl ammation 218,219. From other molecules, 
the upregulation of IL10, IL12, IL18, macrophage-colony stimulating 
factor (M-CSF), IFNG, and the downregulation of IL4, associate with AR 
204,220,221. In addition in other studies, molecules IFNG, sIL1RA, IL2, sIL2R, 
IL3, IL4, IL6, sIL6R, IL10, TGFB2, TNF have not associated with AR 
when studied with ELISA 222,223. However, internationally transplantation 
centres do not use any of these routinely.
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1.6.3 Fluorescence activated cell sorting
In fl uorescence-activated cell sorting (FACS) a monocellular stream 
of cells, platelets or other microscopic particulate elements is passed 
through a beam of laser light of a computerised instrument which 
categorises them by size and form. Cells can be labelled with fl uorescent 
dye and a laser based detector system used to excite fl uorescence and 
give fl uorescent cell droplets an electric charge. Cells can subsequently 
be separated and collected and/or counted 224. Anti-HLA antibodies can 
be detected using FACS analysis. In one application, patient serum reacts 
with beads coated with specifi c HLA antigens and anti-HLA antibodies 
are detected by fl uorescence-conjugated anti IgG or IgM antibodies 225. 
If antibodies are found these can be further specifi ed to certain HLA 
antigens with another FACS analysis using beads coated with single HLA 
antigens 226. High titer post-Tx HLA antibodies monitored by FACS bead 
analysis are associated with increased rejection incidence 227.
AR diagnostics with FACS analysis is based on specifi c antibodies, 
which detect their antigens at the surface or inside recipient cells. The 
T lymphocyte surface molecule CD69, a marker for T cell activation, 
associates with AR 228. Other associations with AR are downregulation of 
CD45 and upregulation of CD61, CD63 and PAC-1 229,230.
1.6.4 Mass spectrometry
Mass spectrometry measures the mass-to-charge ratio of ions. The main 
components of a mass spectrometer are an ionization source, a mass 
analyzer, and a detector system 231. All methods described above have 
been applied to the candidate molecules derived from studies where 
the known pathways of AR or alloimmunity were investigated. A recent 
research approach that has become feasible for well-funded research 
centres is global protein analysis based on mass spectrometry with 
or without two-dimensional gel electrophoresis. Global urine protein 
profi ling has been proposed as a potential non-invasive method for
AR monitoring in kidney Tx, and several studies have been published 232-
239. However, large consortiums have yet to publish their results (www.
allomark.ubc.ca/ and www.genetics.ucla.edu/transplant-genomics/
research/programs/project2.php). They may discover novel molecules 
associated with AR that can be monitored with routinely used methods 
like ELISA AR and other outcomes.
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1.6.5 TaqMan real-time quantitative polymerase chain 
reaction
TaqMan RT-QPCR (from now on referred to as RT-QPCR) is based on 
the two sequence specifi c primers and a probe, fl uorescently labelled 
with a reporter and quencher dye. In the PCR extension phase Taq 
polymerase cleaves the hybridized probe and releases the reporter dye 
for fl uorescence detection 240. Real-time quantifi cation can be done with 
various instruments that vary in excitation and emission wavelengths 
available, speed, number of reactions that can be run in parallel, and 
the reaction container. However, the software and performance of these 
instruments are basically identical 241. The statistical analysis of RT-QPCR 
has not reached a consensus, with standard curve and deltadeltaCt 
relative expression methods being most commonly used 242. In the 
standard curve method the effi ciency of PCR reactions is taken into 
account by running known dilutions of the studied gene and a reference 
gene from one sample in every RT-QPCR run. In the deltadeltaCt method 
the effi ciency of PCR reactions is validated to be the same in the studied 
gene and the reference gene and dilutions are not run after validation 
run 243.
RT-QPCR studies in the kidney Tx setting for AR markers are listed 
in Table 3. Results may refl ect different sources of sample material, 
like kidney biopsy, urine or different blood components, and different 
methods for RT-QPCR. Studies relevant to this thesis are discussed in 
more detail in Results and Discussion.
1.6.6 Microarray
Microarray is quite young as a method , the results of the fi rst self-made 
cDNA arrays being published in 1995 244. Commercially manufactured 
oligoarrays, in particular those by Affymetrix, together with centralised 
core facilities have made the technique available to all users. Even though 
the fi rst kidney Tx microarray studies were all performed with self-made 
cDNA arrays 245-256, studies have also been done with commercially 
available chips 257-259. While gene expression can be studied from any 
cellular source, kidney Tx has obvious sources that may indicate what is 
going on in the graft and recipient, i.e. the blood, urine and biopsy from 
the graft. From these sources RNA is isolated and purifi ed. Often there 
is too little RNA for direct hybridization to the arrays. RNA is therefore 
amplifi ed, followed by labelling and hybridization onto the array chips. A 
scanning apparatus reads the results. The raw data must be normalized 
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using an appropriate technique and the samples are compared by various 
statistical methods depending on the hypothesis. All this processing 
makes the comparison of studies very diffi cult, but not impossible. 
Based on microarray analysis only, there are no commercial laboratory 
tests available that would utilize novel biomarkers. However, there are 
two consortiums developing new biomarkers based on the combination 
of proteomics and genomics (www.allomark.ubc.ca/ and www.genetics.
ucla.edu/transplant-genomics/research/programs/project2.php), and if 
clinically relevant, their results are to be made available as a commercial 
test package.
Many candidate gene markers are expressed in such low quantities 
that not all microarrays can detect the expression of the studied genes. 
These include many cytokines which are major contributors to the 
rejection process. However, RT-QPCR can be used to quantify the low 
expressing genes 260.
Until now (November 2007), four studies have investigated clinical 
rejection but not subclinical rejection in human kidney Tx using human 
samples in microarrays 248,252,261,257. All have been done with different 
microarray platforms and only one 257 has reported a comparison of 
biopsy to peripheral blood leukocyte (PBL) samples. The comparison of 
immune response genes in the microarray studies shows that different 
genes are signifi cantly upregulated or downregulated (Table 4). The 
biomarkers in Transplantation and Transplant Genomics Collaborative 
Groups are conducting a whole genome expression study from kidney 
Tx recipients and donors (www.allomark.ubc.ca/ and www.genetics.
ucla.edu/transplant-genomics/research/programs/project1.php). Rapid 
advances in technology may bring expression analysis into clinical use 
in the next few decades 263.
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2 AIMS OF THE STUDY
The present thesis investigates the role of genetic factors in the 
clinical outcome of kidney Tx. In addition to the currently performed 
histocompatibility testing several other genetic factors may infl uence the 
outcome of kidney Tx and these factors could potentially be analysed 
and the results used to improve patient care.
We hypothesized that cytokine and/or thrombosis associated gene 
polymorphisms may predict the outcome of kidney Tx in adults, because 
cytokines are major mediators of immunological responses in Tx, in 
CMV infection and cytokines and coagulation cascade molecules are 
mediators of immunological responses in the vessels of transplanted 
organs.
In addition, we hypothesised that by studying gene expression 
quantities on blood samples using microarrays and/or RT-QPCR, we 
could determine the clinical applicability of a non-invasive method to 
diagnose AR or SCR in kidney Tx.
Spesifi c aims:
1) To study the association between spesifi c SNPs in genes TNF, 
TGFB1, IL10, IL6, IFNG, F5, F2, F13A1, PROC, TFPI, and MTHFR and 
outcomes in kidney Tx.
2) To study the association between AR and gene expression of Per, 
FL, GB, Gra, CD154, ICOS, CTLA4, and PD-1.
3) To study the association between SCR and gene expression of 
CD154, ICOS, immunologically related genes, and whole genome gene 
expression.
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3 PATIENTS
Study I. The retrospective study comprised 291 adult cadaver kidney 
recipients and their 206 donors transplanted between 1999 and 2002 at 
the Renal Transplant Unit of Helsinki University Hospital, Finland.
Study II. The retrospective study comprised 71 CMV seronegative 
recipients of kidney grafts from 62 CMV seropositive donors transplanted 
between 1999 and 2002 at the Renal Transplant Unit of Helsinki University 
Hospital, Finland.
Study III. The prospective study comprised 50 adult renal graft 
recipients transplanted between 2001 and 2005 at the Renal Transplant 
Unit of Helsinki University Hospital, Finland.
Study IV. The retrospective study comprised 772 adult cadaver kidney 
Txs for 764 recipients (eight recipients had 2 Txs during the study period) 
and their 462 donors transplanted between 1999 and 2003 at the Renal 
Transplant Unit of Helsinki University Hospital, Finland.
Study V. The prospective study comprised 31 consecutive paediatric 
kidney allograft recipients transplanted between 2003 and 2006 at the 
Hospital for Children and Adolescents of Helsinki University Hospital, 
Finland.
4 ETHICAL PERMITS
Ethical permits for the studies were obtained from the relevant Ethical 
Committees of Helsinki University Hospital.
44
5 METHODS
5.1 Isolation of DNA (I, II, IV)
Whole blood samples were originally taken before transplantation for 
histocompatibility testing. The extracted DNA or buffy coats from citrate 
anticoagulated peripheral blood were stored at -20°C. DNA was extracted 
using the QIAamp DNA Blood Mini Kit (QIAGEN Inc, CA) or the FlexiGene 
DNA Kit (QIAGEN Inc, CA, USA).
5.2 Human leukocyte antigen typing (I)
For HLA-A and HLA-B typing serological lymphocytotoxicity method 
and for HLA-DRB1 typing INNO-LiPA HLA-DRB1 kit were used (Immuno 
Diagnostic Oy, Hämeenlinna, Finland).
5.3 Determination of single nucleotide 
polymorphisms (I, II, IV)
The SNPs for this study were chosen based on literature review of most 
promising candidate gene polymorphisms predicting the outcome of 
kidney Tx. Genetic variations in TNF G(-308)A, TGFB1 T(+869)C and 
C(+915)G, IL10 G(-1082)A, IL10 C(-819)T, and C(-592)A, IL6 G(-174)C, 
and IFNG T(+874)A genes of recipients and donors of studies I and II 
were determined using the Cytokine Genotyping Kit (One Lambda Inc. 
CA, USA). Study IV recipients and donors were genotyped for F5 G1691A 
rs6025, F5 A4070G rs1800595, F2 G20210A rs1799963, F13A1 G204T 
rs5985, PROC T8853G, TFPI C536T, and MTHFR C677T rs1801133, 
and those not included in study I also for TNF G(-308)A rs1800629, 
IL10 A(-1082)G rs1800896, IL10 C(-592)A rs1800872, and IL6 
C(-174)G rs1800795 at the Finnish Genome Centre, University of Helsinki, 
Finland, using the Sequenom MassARRAY system, based on MALDI-
TOF technology and primer extension chemistry 292. In addition, a few 
samples were only or also tested for F5 G1691A rs6025 and F2 G20210A 
rs1799963 at the Thrombosis Laboratory of the Finnish Red Cross Blood 
Service using a Factor V Leiden Kit and Factor II (Prothrombin) G20210A 
Kit (LightCycler® Instrument, Roche Diagnostics GmbH, Mannheim, 
Germany).
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5.4 Isolation, quantifi cation and validation of RNA 
from whole blood (III, V)
In study III 119 and in study IV 52 whole blood samples were drawn 
into Paxgene Blood RNA tubes (PreAnalytiX, Qiagen Nordic) and stored 
within 24 hours at -70°C until RNA purifi cation. RNA was purifi ed using 
the Paxgene Blood RNA kit (PreAnalytiX, Qiagen Nordic) according to 
the kit protocol and with an on-column DNase I treatment. The RNA was 
quantifi ed with a GeneQuant™ pro RNA/DNA Calculator (GE Healthcare, 
Finland). The integrity of the isolated RNA was verifi ed by electrophoresis 
using ssRNA Ladder Sample Buffer and ssRNA Ladder (New England 
Biolabs, USA).
5.5 Real-time quantitative polymerase chain 
reaction (III, V)
Synthesis of cDNA from isolated total RNA was done with a High 
Capacity cDNA Archive Kit (Applied Biosystems, Finland) according 
to the manufacturer’s instructions. The relative gene expression was 
quantifi ed using TaqMan Gene Expression Assays (Applied Biosystems, 
Finland), TaqMan Universal PCR Master Mix with no AmpErase UNG 
(Applied Biosystems, Finland) and ABI PRISM 7000. The probe and 
primer assays used in the studies are listed in Table 5. The endogenous 
control gene PGK1 was chosen from a TaqMan Human Endogenous 
Control Plate (Applied Biosystems, Finland) as the stably expressed gene 
among three recipients with a concurrent rejection episode and their 
post-treatment samples. The relative expression was calculated using 
the standard curve method (User Bulletin 2, P/N 4303859B, Applied 
Biosystems) using one non-patient volunteer as a calibrator sample.
46
Table 5. Quantifi ed genes in studies III and V.
Gene Abbrevia tions Assay 
identifi cation 
code
perforin 1 PRF1, Per Hs00169473_m1
fas ligand, tumor necrosis factor (ligand) 
superfamily, member 6
FASLG, FL Hs00181225_m1
granzyme B GZMB, GB Hs00188051_m1
Granulysin GNLY, Gra Hs00246266_m1
tumor necrosis factor (ligand) 
superfamily, member 5
CD40LG, CD154 Hs00163934_m1
inducible T cell co-stimulator ICOS Hs00359999_m1
cytotoxic T-lymphocyte-associated 
protein 4
CTLA4 Hs00175480_m1
programmed cell death 1 PDCD1, PD-1 Hs00169472_m1
phosphoglycerate kinase 1 PGK1 Hs99999906_m1
transformer-2 alpha TRA2A Hs00203263_m1
interferon regulatory factor 2 binding 
protein 2
IRF2BP2 Hs00766250_g1
myristoylated alanine-rich protein kinase 
C substrate
MARCKS Hs00158993_m1
transportin 1 TNPO1 Hs01007848_g1
solute carrier family 8 member 1 SLC8A1 Hs01062251_m1
homeodomain interacting protein kinase 
1
HIPK1 Hs00380232_m1
Calreticulin CALR Hs00944361_g1
IQ motif containing GTPase activating 
protein 1
IQGAP1 Hs00896582_g1
Dcr-1 homolog (Drosophila) DICER1 Hs00998583_g1
lysophospholipase I LYPLA1 Hs00377829_g1
PRO1073 protein/metastasis associated 
lung adenocarcinoma transcript 1 (non-
coding RNA)
PRO1073/
MALAT1
Hs00273907_s1
CD3e molecule, epsilon
(CD3-TCR complex)
CD3E Hs00167894_m1
B-cell CLL/lymphoma 2-like 1 BCL2L1 Hs00169141_m1
polycomb group ring fi nger 5 PCGF5 Hs00260713_m1
CGI-69 protein CGI-69 Hs00924962_g1
BCL2-associated athanogene BAG1 Hs01105460_g1
N-ethylmaleimide-sensitive factor 
attachment protein alpha
NAPA Hs00943303_m1
FK506 binding protein 8 38kDa FKBP8 Hs01014666_g1
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5.6  Low-density array (V)
RT-QPCR from 90 immune-related and six housekeeping genes 18S 
ribosomal RNA, beta actin, glyceraldehyde-3-phosphate dehydrogenase, 
PGK1, beta glucuronidase and transferrin receptor was performed in 
a low-density array format at the Section for Medical Genetics and 
Molecular Medicine, University of Bergen, Norway, according to the 
manufacturer’s protocol (TaqMan® Low Density Human Immune Panel 
card, 4370573, Applied Biosystems). The amount of cDNA counted from 
RNA concentration was 1 μg per card.
5.7  Microarray (V)
After isolation, 5 μg of RNA was treated using the Globin Reduction 
Protocol according to the manufacturer's directions (Globin Reduction 
Protocol: A Method for Processing Whole Blood RNA Samples for 
Improved Array Results Part No. 701497 Rev. 2, www.affymetrix.com). 
All experiments were performed using Affymetrix Human Genome 
U133 Plus 2.0 oligonucleotide arrays according to the manufacturer's 
directions. Sample labelling and hybridisation were carried out at the 
Finnish DNA Microarray Centre at Turku Centre for Biotechnology, Turku, 
Finland.
The Affymetrix GeneChip Operating Software (GCOS) detection 
algorithm was used to determine the presence or absence of expression 
for each transcript. A transcript with either a present or a marginal 
detection call was considered expressed. The complete gene expression 
data are available at http://qp01.novogroup.com/vpu. The GCOS change 
algorithm was used to compare the data of patients with rejection at three 
months post-Tx against the same patient’s six-month post-Tx sample 
data, or against the data of patients without rejection at three months, 
to detect and quantify changes in gene expression. The transcripts 
assigned with increased, decreased, marginally increased or marginally 
decreased change calls were considered differentially expressed. Only 
those genes that were increased or decreased by at least a two-fold 
change in all rejection patients compared with normal patients at three 
or six months were studied further.
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5.8  Statistical analyses (I - V)
Preliminary power analysis was done with the Genetic Power Calculator 
293 based on known baseline characteristics (odds ratio 3 - 10 according 
to outcome and SNP) and results published by others on the incidence 
of the studied factors (IV) 170,175,182. The Hardy-Weinberg equilibrium of 
genotypes was tested using Fisher’s Exact Test (I, II, IV). Descriptive 
statistics were used to describe the baseline characteristics and duration 
of follow-up. In bivariate analysis, Fisher’s exact test was used to compare 
the occurrence of AR, thrombosis, infarction or composite endpoint 
from the above with respect to categorical baseline characteristics. 
Corrections for multiple testing were not done and a P-value <0.05 was 
considered statistically signifi cant in studies I - III and V. The correction 
for multiple testing was done using the Bonferroni correction according to 
11 DNA polymorphisms studied in 9 candidate genes without taking into 
consideration the number of studied phenotypes that give statistically 
signifi cant P-values less than 0.0045 (IV). In addition, the distributions of 
continuous baseline characteristics with respect to studied complications 
and available laboratory results after Tx were compared using a Mann-
Whitney U test and a Kruskall-Wallis test. Bivariate survival analysis 
was done with a Kaplan-Meier analysis and log rank test (II - IV). To 
adjust for confounding factors, multivariate logistic regression (I, II, 
IV) and Cox proportional hazards models (II, IV) were used to analyse 
the risk factors associated with AR, thrombosis, infarction, composite 
endpoint or 1st year GS after Tx. Statistical analyses were done using 
SPSS 13.0.1 (SPSS, Finland), StatsDirect 1.8.10 (StatsDirect, UK) or 
MedCalc 8.1 (MedCalc Software, Belgium). 
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6 RESULTS AND DISCUSSION
6.1 Acute rejection (I, IV)
Studies I and IV aimed to fi nd associations between SNPs and AR, 
thrombosis, infarction, or GS. Such fi ndings would justify further study 
of the associations prospectively in a larger study population. Eventually 
it might be possible to determine whether asymptomatic patients 
would benefi t from individualized immunosuppression, antithrombotic 
prophylaxis or other medication according to their genetic status.
The overall incidence of AR in the study I was 17.2 %, i.e. 50 episodes. 
Two pre-transplantation factors were found to increase the risk of AR: 
presence of 3 - 4 HLA-A, -B or -DR mismatches (MM) (OR 1.8, 95 % CI 
1.1 – 3.1 and P = 0.027), and a graft from CMV-seronegative donor to 
CMV-seronegative recipient increased the risk of AR (OR 2.2, 95 % CI 1.2 
- 4.1, P = 0.038).
The cytokine gene polymorphisms studied in study I were TNF G(-308)A, 
TGFB1 T(+869)C and C(+915)G, IL10 G(-1082)A, IL10 C(-819)T, and
C(-592)A, IL6 G(-174)C, and IFNG T(+874)A. TNF and IL10 are the 
cytokine genes previously reported as most likely to have relevance for 
allograft outcome 154. In addition, IFNG, IL6 and TGFB1 have in some 
studies been found to have an impact on the development of AR 96,128,135,294. 
All of these studies were relatively small of under 200 recipient or donor 
participants, the obtained p-values were rarely clearly less than 0.05 or 
corrected for multiple testing and usually derived from only a few SNPs. 
However, these were the SNPs most studied and associated positively to 
kidney Tx outcomes so we limited the scope of the study to these fi ve 
genes.
Among 772 transplant recipients in study IV, an AR episode was 
diagnosed in 139 (18%) subjects. We genotyped F5 G1691A, F5 A4070G, 
F2 G20210A, F13A1 G204T, PROC T8853G, TFPI C536T, MTHFR C677T, 
TNF G(-308)A, IL10 A(-1082)G, IL10 C(-592)A, and IL6 C(-174)G, 
giving a total of 11 SNPs in nine genes in the study IV. This resulted in a 
Bonferroni corrected signifi cant P-value of 0.005. None of the SNPs were 
signifi cantly associated with AR. The level of HLA mismatch (Hazard ratio 
(HR) 2.3, 95% CI 1.6 - 3.3), DGF (HR 1.8, 95% CI 1.2 - 2.6) and the 
age of recipient (HR 0.97, 95% CI 0.96 - 0.99) showed association with 
AR by Cox proportional hazard model. The last mentioned two known 
risk factors were also statistically signifi cant in bivariate analysis and in 
logistic regression analysis.
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6.1.1 Only a few gene polymorphisms were associated 
with acute rejection (I)
The distribution of the frequencies of the cytokine genotypes was found 
to be in the Hardy-Weinberg equilibrium. There were no differences 
in frequencies between the recipients and donors. The cytokine 
polymorphisms at genotype level in the recipient and respective donor 
were compared by univariate analysis with respect to AR status (I). The 
recipient TNF -308AA genotype was statistically signifi cantly associated 
with AR (Rejection rate 80%, OR = 5.0, P = 0.0034).
Chronic rejection triggers TNF production in stimulated monocyte 
cultures of affected patients 295. In addition, TNF is more often detected 
in plasma and urine in renal allograft recipients with AR 296. The dbSNP 
lists more than 37 polymorphisms at the 5’ end of the TNF gene, of which 
the G(–308)A (rs1800629) SNP is probably the most frequently studied. 
After HapMap project and other extensive resequencing projects, it is 
now known that only 3 SNPs (among them -308) are needed to capture 
80 % of the common genetic variation in TNF overall among European–
Americans 297. More extensive approach by studying all the TNF SNPs 
in a small number of samples and defi ning the LD between them was 
out of reach of this study, even though this would have given more 
information about the defi nitive SNP affecting the association between 
TNF and AR. TNF -308A allele is considered a six- to seven-fold stronger 
activator of transcription than the more common G allele 110. However, 
Bayley et al. reported that the -308 SNP had no functional relevance for 
TNF transcription 298,299. Probably due to confl icting results in expression 
studies, the reported effects of TNF A(-308)G SNP on Tx outcome have 
been variable. The -308 SNP was found to be associated with AR in 
heart 300 and renal allograft recipients and the A allele predisposed 
to AR in these studies 96,112-114. A combination of TNF -308 AA or GA 
genotypes with IL10 -1082AA genotype in the same heart Tx patient 
signifi cantly increased AR risk 301. However, several studies of kidney 
and heart Tx patients have failed to fi nd an association of -308 SNP 
with AR 98,124,126,127.
Some of the studies have included small groups (100 - 200 
participants) of uniform genetic subjects, e.g. Caucasians and African-
Americans, having genetic backgrounds with different risk factors 98. 
Further, multivariate analysis has not always been performed due to 
missing clinical factors (known or hypothesized confounding factors) or 
insuffi cient numbers of subjects (not enough power perform subgroup 
analyses) 96,114,127. The multivariate analysis in the present study was 
done with both a prior hypothesis and hypothesis-free approaches. 
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However, the impact of genetic factors in predicting AR was small and 
did not exceed the impact of known clinical factors.
In published reports the genotype frequencies that may suggest 
that the Hardy-Weinberg equilibrium is not fulfi lled are usually not 
listed, probably due to lack of space or because of being perceived as 
uninteresting to a journal audience. In addition, the studied outcome 
incidences vary to a large degree, probably refl ecting major variances 
in the amount of immunosuppression administered to patients 124,126. 
This may mask or infl ate the reported importance of the studied 
SNPs by altering the observed association of outcome with gene 
polymorphisms.
TNF and HLA genes are in strong LD 302. Only some studies take this 
into account as a confounding effect when considering HLA mismatches 
between recipients and donors and TNF gene polymorphisms 
associating with outcome 96,112,127,301,303. The TNF -308A-allele lies within 
the HLA-A1-B8-DR3-DQ2 extended haplotype which is associated with 
various autoimmune diseases e.g. IgA defi ciency and systemic lupus 
erythematosus 304. In our study, the HLA-A1-B8-DR3 haplotype was not 
associated with AR despite the recipient TNF -308AA genotype being 
associated with AR.
In addition, IL10 polymorphisms have been reported to associate 
with AR in several reports 98,112,123,134, but not in others 96,113,124,126,127,135. 
Contradictory results may in part be result of insuffi ciently powered 
studies. Gene polymorphisms in the IL10 gene have been found to 
constitute conserved haplotypes in many populations (only certain 
haplotypes are found), combined (low and intermediate or high and 
intermediate are combined) or separate genotypes associating with low, 
intermediate or high IL10 protein production in vitro 305. We did not 
fi nd association between IL10 -1082AA (low producer) or AG/GG (high 
producers) genotypes and AR, whether or not they occurred together with 
the TNF -308 AA/AG (high producers) or GG (low producer) genotypes. 
The IL10 low/TNF high profi le associates with AR in heart Tx 301 and 
the IL10 high/TNF high profi le associates with AR in kidney Tx 112. The 
association with AR of IL10 gene polymorphism may be infl uenced by 
the allograft, the immunosuppressants used, the criteria of AR diagnosis, 
and other unknown or known factors between hospitals and studies.
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6.1.2 Genetic variation in thrombosis-associated or 
cytokine genes did not associate with AR (IV)
Heidenreich et al. reported a medium sized prospective study showing 
an association between AR and F5 G1691A, F2 G20210A or MTHFR 
C677T in 165 kidney Tx recipients 175. Their study had an exceptionally 
high incidence of AR, 44% as compared to 18% in our study, which may 
indicate under-immunosuppression in their study. However, our results 
were similar to the fi ndings of Pherwani et al. who found no association 
in recipients or donors between AR and F5 G1691A, F2 G20210A or 
MTHFR C677T. They reported a retrospective study on paediatric and 
adult patients who were given heparin for postoperative thrombosis 
prophylaxis. They did not report overall AR incidence, but their fi rst-
year graft failure rate due to AR was 4.1% compared to only 1.4% in our 
study, suggesting that different immunosuppression and HLA matching 
policy was used 178.
An advantage of our study was that the Finnish population is genetically 
relatively homogeneous, which probably helps identifi cation of weaker 
associations between genetic factors and disease outcome 306. One 
might postulate that in the absence of statistically signifi cant genetic 
associations of the marker polymorphism in the Finnish population, these 
cannot be found in genetically more mixed populations either, assuming 
equal prevalences of the marker polymorphism in the populations. 
The converse may also be true, i.e. that an association of the marker 
polymorphism signifi cant in the Finnish population may not be found in 
a more mixed population.
A more ambitious approach than analysis of candidate genes would be 
a genome-wide analysis of gene polymorphisms, as other genes involved 
in the thrombotic cascade may associate with AR. However, we studied 
11 DNA polymorphisms in nine candidate genes, including eight SNPs 
not previously studied in a kidney Tx setting, making our investigation 
the most extensive study of thrombosis-associated polymorphisms in 
adult kidney Tx so far.
Despite almost 800 Txs in the study IV, the AR incidence was only 
18% and several SNPs were found to be quite rare (four rare allele 
incidences <2%). A larger study material is therefore needed for defi nite 
conclusions. We could not replicate the association found in our study 
I between TNF SNP and rejection. This may possibly be due to the fi rst 
fi nding being a false positive result. Other possible reasons for non-
replication are not correcting for multiple testing in the fi rst study and 
the infl ated OR in the small sample size of TNF -308AA genotype carriers. 
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In conclusion, we were unable to fi nd associations between SNPs and AR 
in the retrospective adult kidney Tx setting. We could not provide data 
to support the routine determination of gene polymorphisms before Tx 
for AR prediction.
6.2 Genetic variation in interleukin 10 but not 
in other cytokine genes predisposed to CMV 
infection (II)
We aimed to predict the incidence and timing of CMV infection in adult 
deceased kidney Tx by analyzing cytokine gene polymorphisms, because 
cytokines are major mediators of immunological responses to CMV 
infection and CMV infection may impair kidney graft function after Tx. CMV 
diagnosis was defi ned as clinical CMV suspicion (fever and/or elevated 
serum creatinine value without rejection) and positive pp65 antigenaemia 
test. This study targeted the high-risk group of CMV serology negative 
recipients (R-), with CMV serology positive (D+) donors. We genotyped 
71 recipients and 62 donors for IL10 G(-1082)A, IL10 C(-819)T, and
C(-592)A, IL6 G(-174)C, and IFNG T(+874)A cytokine gene SNPs. There 
were 24 diagnosed CMV episodes. Of the recipients, 22 received three-
month CMV prophylaxis of gancyclovir or valgancyclovir and fi ve a short 
prophylaxis (6-21 days) during a concurrent AR episode. Three-month 
prophylaxis, immunosuppressive treatment without antibody induction, 
and normal onset of graft function reduced the incidence of CMV, but not 
signifi cantly (P = 0.26, 0.15, and 0.16, respectively) (Fig. 6a-b).
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Figure 6. Kaplan–Meier survival curves of recipient clinical features and donor 
cytokine polymorphisms affecting CMV incidence. a) Long prophylaxis compared to 
no or short prophylaxis, b) immunotherapy (black) and delayed graft function (DGF, 
grey), c) donor IL10 −1082 genotype, and d) donor IFNG +874 genotype. Copyright 
© 2006 Elsevier B.V. All rights reserved 307.
Recipient and donor cytokine polymorphisms were compared by Kaplan-
Meier analysis. The analysis was done between patients with and without 
CMV diagnosis, at genotype and/or phenotype level. The donor IL10 
-1082AA genotype decreased the incidence of CMV (P = 0.031) (Fig. 
6c). The IL10 -1082AA genotype has been associated with low IL10 
cytokine production 308. CMV incidences were three out of 20 (15%) in AA 
and 21 out of 51 (41%) in AG/GG genotypes. The median time to CMV 
diagnosis was 83 days for AA and 45 for AG or GG genotypes (Mann-
Whitney p for trend = 0.072). Further, none of the recipients receiving 
a graft from a donor with IL10 -819TT/-592AA genotype (which is also 
associated with a phenotype of low IL10 cytokine expression) developed 
CMV. However, since there were only fi ve such patients the effect did not 
reach statistical signifi cance (P for trend = 0.051) and would not have 
been clinically relevant. 
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Donor IL6 -174CG/GG and donor IFNG +874TT genotypes (both 
associated with high cytokine expression phenotype) 308 were both 
slightly less common, but not signifi cantly, in cases developing CMV (P = 
0.33, 0.17, respectively) (Fig. 6d). The 66 available recipient genotypes 
did not associate with CMV incidence.
Multivariate analysis with the Cox proportional hazards model gave 
no other variable except donor IL10 -1082AA genotype, which was alone 
signifi cant with respect to reduced incidence of CMV (HR 0.3, 95% CI 
0.09 – 0.96, P = 0.043).
Human IL10 is an immunosuppressive cytokine which suppresses 
cytokine and chemokine production by macrophages, T-helper cells, NK 
cells and peripheral blood mononuclear cells 309. CMV encodes a homologue 
of human IL10, which the virus uses to evade immune surveillance 310. 
The homologue probably allows the virus to survive in infected cells, 
replicate and develop a full infection 311. Accordingly, a genetically CMV 
susceptible mouse strain produced higher quantities of IL10 leading to 
the Th2 type of immunoresponse compared to a mouse strain genetically 
resistant to CMV 312. Thus, in the viral microenvironment, high quantities 
of IL10 probably augment the spread of infection. In our study, the IL10 
low production genotype in donors was found to protect against CMV 
reactivation. It seems possible that CMV infected cells in donor organs 
produce extra IL10 with an effect similar to the viral homologue.
On the other hand, Conti et al. reported that systemic production of 
IL10 by recipient cells stimulated B cell proliferation, antibody secretion 
and development of cytotoxic T cells 309. However, these late occurring 
systemic responses to infection probably limit the extent of the infection 
and damage, rather than inhibiting the early stages of CMV reactivation. 
The genetic background of the recipient can be assumed to infl uence 
more the systemic response than that occurring locally within the graft 
with donor background.
The known predisposing factors in kidney allograft recipients for CMV 
disease are high-dose immunosuppressive protocol, co-morbidity, viral 
load, and DGF 313,314. In a large meta-analysis, anti-viral prophylaxis 
signifi cantly reduced the risk of CMV disease (19 trials, 1981 patients; 
relative risk 0.42 [95% CI 0.34–0.52]) and infection (17 trials, 1786 
patients; 0.61 [0.48–0.77]) 315. We found only a trend-level association 
between prophylaxis and reduced CMV incidence, probably due to the 
relatively small patient (71) population.
In conclusion, we found that donor IL10 -1082AA genotype was 
associated with a reduced incidence of CMV in CMV-seronegative 
recipients of allografts from seropositive donors. Further and more 
extensive investigations may confi rm the clinical relevance of this risk 
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factor. Moreover, the genetic background of the donor may help to assess 
post-Tx risks in kidney allograft recipients.
6.3 Genetic variation in thrombosis-associated or 
cytokine gene polymorphism did not predispose 
to thrombosis (IV)
In this study there were 38 (4.9%) recipients diagnosed with venous 
thrombosis and/or pulmonary embolism. We genotyped F5 G1691A, 
F5 A4070G, F2 G20210A, F13A1 G204T, PROC T8853G, TFPI C536T, 
MTHFR C677T, TNF G(-308)A, IL10 A(-1082)G, IL10 C(-592)A, and IL6 
C(-174)G, totalling 11 SNPs in nine genes. Of the non-genetic factors, 
patient age over 50 years increased the risk of suffering a thrombotic 
complication (OR 2.8, 95% CI 1.3 - 5.8). The SNPs studied in the 
recipients or donors were not signifi cantly associated with any of the 
studied outcomes after correcting for multiple testing.
Increased risk for thrombosis in renal transplant recipients and 
association with F5 G1691A has been found in two reports 170,173. These 
studies had 300 and 202 recipients, and 26% and 11% incidence of 
thrombosis, respectively. Sample size was moderate in both, but by 
current standards the thrombosis incidence was exceptionally high, 
which may augment the risk associated with F5 G1691A. A negative 
association was found in three reported studies involving 109, 394, 
and 509 recipients (and also 457 donors in the last study) with 27%, 
6%, and 8% incidences of thrombosis, respectively 172,174,178. The fi rst 
two negative studies probably did not have enough statistical power to 
detect positive association and in the last study all the recipients had 
heparin prophylaxis after surgery, which probably prevented all renal 
vein thromboses and immobility-based thromboses. 
The effect of F5 G1691A mutation (FVL) has been well established in 
thrombosis patients and their relatives to increase the risk of thrombosis 
by seven- to 80-fold, whether heterozygous or homozygous for the 
mutation 316. ESRD patients with increased susceptibility to thrombosis 
are commonly identifi ed during haemodialysis with problems of 
blood clotting in dialysis catheters. However, whether anticoagulation 
medication is continued after Tx depends on the centre, in the absence 
of uniform international consensus 88.
Pherwani et al. reported negative F2 G20210A mutation association 
with thrombosis in 562 renal transplant recipients and 457 donors 178. In 
their study all recipients had heparin prophylaxis for thrombosis, which 
may modify the negative genetic association. Even though F2 G20210A 
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mutation may not specifi cally increase the risk of thrombosis in renal Tx 
recipients, it may decrease GS by association with other complications 
like vascular rejection 88. However, F2 G20210A mutation heterozygosity 
is associated with a 2.8-fold increased risk of thrombosis compared with 
non-mutation carriers 316. 
Apart from the present report (IV), there are no kidney Tx studies 
regarding the association between MTHFR C677T polymorphism and 
thrombosis. However, a recent meta-analysis of published epidemiological 
studies of 8364 fi rst-time or recurrent thrombosis cases and 12 468 
controls found that the 677TT genotype was associated with a 20% 
higher risk of thrombosis compared with the 677CC genotype. This 
may be modifi ed by the nutritional intake of folate and ribofl avin, which 
can cause contradictory association results between populations with 
different diets 317. Finnish kidney Tx patients often take multivitamins 
including low doses of folate and ribofl avin, which may in part explain 
our negative results if low doses are considered to be effective.
6.3.1 Thrombosis-associated or cytokine gene 
polymorphisms did not predispose to infarction 
(IV)
In this study there were 48 recipients with cerebral infarcts (35.4%), 
with myocardial infarcts (62.5%), and with kidney infarcts (2.1%). Non-
genetic or genetic factors of the recipients and donors did not associate 
with infarcts.
These results are in accordance with studies that did not fi nd association 
between infarction and IL6 G(-174)C 318,319, or F5 A4070G 320, or F5 
G1691A 319, or F13A1 G204T, IL10 A(-1082)G, IL10 C(-592)A, MTHFR 
C677T and F2 G20210A 319. There is only one published study on kidney 
Tx patients and it did not report association between F5 G1691A and 
myocardial infarction 170. Studies fi nding association between infarction 
and F5 G1691A 321, or MTHFR C677T 183 did not study kidney Tx outcomes 
but myocardial infarction among other cardiovascular diseases. In one 
genome-wide association study LTA associated with infarction in a Japanese 
population 322 but not in a replication study also among Japanese 323. This 
non-replication may be due to different diagnostic criteria and lack of 
statistical power 324.
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6.3.2 Thrombosis-associated or cytokine gene 
polymorphisms were not associated with graft 
survival
Graft loss within the fi rst year after Tx was due to AR, thrombosis or 
infarct in 28 (62%) out of 45 losses (other graft losses were due to nine 
patient deaths and eight other causes, e.g. primary disease relapse). We 
genotyped F5 G1691A, F5 A4070G, F2 G20210A, F13A1 G204T, PROC 
T8853G, TFPI C536T, MTHFR C677T, TNF G(-308)A, IL10 A(-1082)G, 
IL10 C(-592)A, and IL6 C(-174)G, totalling 11 SNPs from nine genes. 
The one-year GS was not signifi cantly infl uenced by the studied genetic 
or non-genetic factors of recipients or donors analysed by the bivariate 
analyses.
Recently, one large multicentre study compared the association
between the GS of 676 cadaver kidney fi rst or 651 retransplants and
F5 G1691A, F2 G20210A or MTHFR C677T polymorphisms. In this
study F2 G20210A associated with the three-year survival of fi rst 
transplants 180. We analysed our data separately for the fi rst and 
retransplant subgroups but did not fi nd an association with GS. This 
may have been due to our small study size.
In addition, FVL was reported to associate with GS in a study of 109 
kidney recipients with a high incidence (27%) of vascular rejection 172. 
In our study the vascular rejection incidence was 2%, which probably 
affected our negative fi nding. Our results are similar to three other 
studies which were also unable to fi nd association between GS and
FVL 175,177,178.
Two further studies reported association between F2 G20210A and 
GS 175,182. The fi rst had a 13% retransplant rate compared to our rate of 
1%. The latter study was a prospective investigation with high AR (44%, 
ours 18%) and acute vascular rejection (28%, ours 2%) incidences, 
suggesting under-immunosuppression or over-selection of patients with 
additional risk factors. A study reporting negative association between 
F2 and GS 178 involved the use of heparin post-Tx thrombosis prophylaxis 
which may have reduced the incidence of fatal complications post-Tx. 
In our study most patients were on acetylsalicylic acid, which may have 
reduced graft thrombosis and cardiac complication incidences leading to 
graft loss.
Although several studies have reported an association between 
MTHFR C677T and homocysteine or lipid levels 184-192, none has reported 
a positive association between MTHFR C677T and GS 175,193,194,196. Most 
study patients take multivitamins including low doses of folic acid 
and ribofl avin, which may reduce homocysteine levels irrespective 
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of MTHFR C677T genotype status. The MTHFR C677T genotype may 
have an infl uence on GS through increased (OR = 1.2) susceptibility to 
cardiovascular complications 325, probably warranting large prospective 
studies including diet and multivitamin use information.
Cytokine gene polymorphisms were not associated with GS in our 
study. Similarly, several studies have reported negative associations 
between TNF G(-308)A, IL10 G(-1082)A, C(-592)A, IL6 G(-174)C and 
GS 96,100,116,117,141,326. Mytilineos et al. reported an association between 59 
retransplanted TNF -308AA carriers and GS 117, which we were not able 
to study as we did not have retransplanted TNF -308AA carriers in the 
study population.
6.4 Gene expression markers showed similar time-
related variance during hospital stay in control 
patients (III)
The aim of this study was to determine whether analysis of whole blood 
gene expression of lymphocyte marker molecules would offer a robust 
means to diagnose AR after kidney Tx. If clinically useful, such a method 
would provide a non-invasive, easy, and rapidly performed test that 
could be routinely applied to detect rejection at an early phase before 
permanent injury has occurred. In particular, collection of whole blood 
into tubes with RNA stabilising solution that can be stored at room 
temperature would allow easy adaptation to routine hospital sample 
collection. 
We decided to test the relevance of this method by investigating 
eight candidate molecular markers: perforin 1 (Per), fas ligand (FL), 
granzyme B (GB), granulysin (Gra), CD40 ligand (CD154), inducible T 
cell co-stimulator (ICOS), cytotoxic T-lymphocyte-associated protein 4 
(CTLA4), and programmed cell death 1 (PD-1). Per, FL, GB and Gra are 
lymphocyte cytotoxic molecules that have a clear role in the molecular 
process of allograft rejection and that have previously been suggested 
to have diagnostic value 327. In addition, we hypothesized that the gene 
expression quantities of co-stimulatory molecules CD154, ICOS, CTLA4, 
and PD-1 associated with T-cell activation would be signifi cantly altered 
at a time of an AR episode and therefore be able to distinguish rejection 
from non-rejection samples. These were chosen based on a literature 
search.
Control patients were studied in order to determine the changes 
in gene expression associated with pre- and post-Tx course without 
rejection. The relative quantity of four costimulatory (ICOS, CD154, 
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CTLA4 and PD-1) and four cytotoxic (FL, Gra, GB and Per) genes followed 
the same general pattern after Tx. There was a rapid decrease of gene 
expression by approximately 50% between day 0 and day 1, followed by 
a slow increase so that by day 21 the levels were again close to those 
on day 0 (Fig. 7).
Figure 7. The relative gene expression quantities of studied genes relative to the d0 
sample of control patients. Error bars represent the standard deviation of replicate 
wells normalised to endogenous control gene and calibrator. Med denotes median. 
Copyright © 2007 Lippincott Williams & Wilkins. All rights reserved 289.
The two studies of serial analysis of whole blood gene expression 
quantities after Tx are in accordance with ours 251,290. One study reported 
lower quantities of granulysin on post-Tx day 1 than before Tx and higher 
levels on day 7 than on day 1 290, and the other noted up-regulation of 
Per and GB in eight paediatric renal allograft recipients between day 1 
and day 30 in peripheral blood leukocyte samples 251. It seems likely that 
the early decrease in whole blood gene expression quantities refl ects 
the massive infi ltration of T-cells expressing the studied markers to the 
transplanted kidney at the time of Tx 328, which is gradually reversed 
as time passes and immunosuppressive medication stabilises the 
situation.
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6.5 The expression of two genes was different in 
rejection patients than in control patients (III)
In order to determine whether AR episodes were associated with changes 
in gene expression, we compared 25 rejection and 15 control patients. 
The gene expression quantities of cytotoxic molecules were lower in the 
rejection patients than in the controls, although the differences were 
not statistically signifi cant (Fig. 8). The gene expression quantities of 
the costimulatory molecules ICOS and CD154 were signifi cantly lower 
Figure 8. The relative gene expression quantity of eight studied genes compared 
between individual control patient medians and rejection patient samples from post-
Tx day 8. The combined box/whisker and dot plots show 10%, 25%, 50% (median), 
75%, and 90% percentiles, all the data points of individual outliers are between 90% 
and 100% percentiles. C, control patients; AR, rejection patients. Copyright © 2007 
Lippincott Williams & Wilkins. All rights reserved 289.
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in rejection patients (P<0.001, both). The gene expression quantity of 
the costimulatory molecules CTLA4 and PD-1 showed no statistically 
signifi cant differences between rejection patients and controls (Fig. 8).
Our study design did not allow us to serially analyse samples taken 
from the same patient until rejection occurred. In the protocol, samples 
of individual patients are calibrated with their own pre-Tx sample and in 
the constellation Per and GB gene expression has been found to increase 
before the onset of an AR episode 283,284. In a similar investigation, CD154 
and ICOS might be better to differentiate rejection from non-rejection 
patients.
Mechanistically, it seems likely that the decreases in CD154 and 
ICOS gene expression in whole blood we observed during rejection 
and/or other complications are due to lymphocytes expressing the 
molecules migrating to the allograft during injury. CD154 and ICOS 
gene expression increases in renal allograft biopsies of recipients with 
subclinical or acute cellular rejection 268, and FL, Gra, GB, Per, CD154, 
ICOS, CTLA4 and PD-1 gene expression increases in SCR and AR biopsy 
material compared to stable allograft biopsies 267,268. Similarly, in kidney 
biopsies CD154 expression increases more during AR episodes than 
during other types of renal dysfunction (cyclosporine toxicity, acute 
tubular necrosis, recurrence of primary disease, vascular complication 
or chronic rejection) 329.
The comparison of our results with data reported by other investigators 
is challenging since there are differences in patient population, 
immunosuppression, sampling schedule, sample type, sample handling 
and the analysis itself 198,330-332. Possibly the single most important 
technical difference between our study and previous investigations is 
that we used a tube pre-fi lled with RNA-stabilising solution to draw 
samples into. To our knowledge there are no previously published results 
utilising this particular method in kidney transplant recipients, making 
direct comparison of results impossible. The whole blood sample drawn 
into the tubes did not give the same transcriptional profi le as kidney 
biopsy, urine cells, isolated blood cells or whole blood in studies utilising 
different technology, probably due to the different sample processing 
method. In particular we were unable to detect the signifi cant increase 
in the expression of cytotoxic gene markers that is usually reported to 
occur during an AR episode 333.
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6.6 Rejection patients differed from non-rejection 
patients with regard to one gene expression 
marker (III)
The 25 rejection patients were compared to the 10 kidney biopsied non-
rejection patients (RS). The gene expression quantities of all cytotoxic 
molecules (except FL, which did not differ) were lower in rejection 
patients; however the differences did not reach statistical signifi cance 
(Fig. 9). The gene expression quantities of costimulatory molecules 
Figure 9. The relative gene expression of the studied genes compared between 
rejection and non-rejection patients. The combined box/whisker and dot plots 
show 10%, 25%, 50% (median), 75%, and 90% percentiles; all the data points of 
individual outliers are between the 0% and 10% or 90% and 100% percentiles. AR, 
rejection patients; RS, non-rejection patients. Copyright © 2007 Lippincott Williams 
& Wilkins. All rights reserved 289.
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CD154 and ICOS were also lower in rejection patients, but only CD154 
reached statistical signifi cance (P = 0.028). The gene expression 
quantities of CTLA4 or PD-1 did not differ signifi cantly (Fig. 9).
In conclusion, we were unable to determine that the use of whole 
blood gene expression of lymphocyte molecules would be feasible for 
the clinical diagnostics of acute kidney allograft rejection. We discovered 
that the whole blood gene expression of costimulatory molecules CD154 
and ICOS reasonably robustly differentiated rejection patients from 
control patients. However, the clinical use of the analysis is limited by 
poor capability to differentiate rejection patients from those with other 
complications causing a suspicion of clinical rejection.
6.7 Candidate gene expression markers did not 
differ between patients with subclinical 
rejection and control patients (V)
The aim of this study was to analyse gene expression differences 
between SCR and non-rejection patients by microarray and RT-QPCR 
in whole blood samples, in order to determine whether the approach 
could be clinically useful as a non-invasive method to diagnose SCR 
in kidney Tx. We measured the relative gene quantities of CD154 
and ICOS from whole blood samples taken three and/or six months 
after Tx. We analysed 31 samples taken at three months. Thirteen of 
these were from patients whose kidney biopsy was classifi ed as SCR. 
Eighteen of the samples were from patients with biopsies showing no 
rejection signs.
At three months, the whole blood CD154 and ICOS expressions in 
patients with or without SCR were not signifi cantly different (medians 
1.16 vs 1.25 and 1.61 vs 1.95 for CD154 and ICOS, respectively) (Fig. 
10). In addition, the three- and six-month samples showed no signifi cant 
expression change in either CD154 or ICOS regardless of whether the 
patient had SCR at three months or not (medians 1.25 vs 1.67 and 1.50 
vs 1.87 for CD154 and ICOS, respectively).
We collected blood samples into tubes pre-fi lled with a RNA-
stabilising solution. These tubes may circumvent the problem of false 
gene expression results caused by the degradation of RNA or activation 
of blood cells during collection, transportation, storage and batch 
processing of samples 334-337. However, whole blood sample results may 
be different to kidney biopsy or urine sample results as the different 
source samples may not carry the same qualitative and/or quantitative 
biomarker information 331.
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We were unable to separate patients with or without SCR with CD154 and 
ICOS expression in whole blood samples, although they separated adult 
kidney Tx with or without clinical rejection in our study III. Subtle gene 
expression changes and/or different molecules involved in subclinical 
compared to clinical rejection episodes may explain the difference in 
results.
6.8 Gene expression markers of the low-density 
array were unable to identify patients with 
subclinical rejection (III)
We performed the LDA of immune genes from fi ve kidney biopsy-proven 
normal, fi ve SCR samples, and one calibrator sample from a healthy 
untransplanted volunteer. Of the 96 genes in the array, at least three 
normal, three SCR samples and the calibrator sample expressed 57 
genes. The only signifi cantly differently expressed (P = 0.04) gene was 
CD3E (CD3e molecule, epsilon [CD3-TCR complex]), which was slightly 
decreased in samples with SCR compared to samples without SCR 
(medians 1.12 vs. 2.65, respectively). For array fi nding validation, we 
measured with single RT-QPCR reactions the relative expression of CD3E 
Figure 10. The relative gene expression quantities of CD154, ICOS, and CD3E in 13 
subclinical rejection and 17 normal samples taken at the three-month clinical visit. 
N, normal patients; SCR, subclinical rejection patients.
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from the above samples and a further 12 normal and seven SCR three-
month samples. The CD3E expression was not statistically signifi cantly 
decreased in samples with SCR compared to samples without SCR 
(medians 1.66 to 2.25, respectively) (Fig. 10).
Since we did not fi nd association between gene expression of 
CD154 or ICOS and SCR, we examined in LDA format the expression 
of immunological genes, including several of the candidate markers for 
rejection proposed by other investigators 268. Although CD3E expression 
was signifi cantly different between patients with and without SCR in 
LDA, we were unable to observe this difference in a larger number of 
samples, probably due to heterogeneous expression. A decreased CD3E 
molecule amount in peripheral blood lymphocytes associates in kidney 
Tx with long-term surviving kidneys 338, while increased CD3E gene 
expression associates with AR 277.
6.9 A robust biomarker specifi c for subclinical 
rejection could not be identifi ed in whole 
genome microarray analysis (III)
We performed two separate hybridisations. The fi rst hybridisation 
consisted of eight paired whole blood samples of four patients. The 
pairwise samples came from patients with SCR in the three-month 
protocol biopsy (Banff grade 1A) and six-month protocol biopsy with 
normal Banff grade. After GCOS analysis, we further analysed all the 
genes with at least two-fold average change. There were 26 probe sets 
representing 20 genes. From these, we quantifi ed with RT-QPCR six 
genes (BCL2L, BAG, CGI69, NAPA, FKBP8, PCGF5) with the largest fold 
change. However, none of the genes expressed signifi cantly differently 
in RT-QPCR.
In the second hybridisation, we processed four whole blood samples 
from patients with a normal three-month protocol biopsy. With GCOS 
analysis we compared these samples to those of four patients with a 
SCR in their three-month biopsy from fi rst hybridisation. From these 
comparisons, we listed all the genes that were common to all the 
samples with signifi cant change between SCR and normal samples. 
We found 29 shared probe sets representing 27 genes. From these, 
we further analysed 11 genes (MALAT1, TRA2A, IRF2BP2, MARCKS, 
TNPO1, SLC8A1, HIPK1, CALR, IQGAP1, DICER1 and LYPLA1) with over 
two-fold change in most patients or the largest average fold change. 
We performed RT-QPCR analysis from the samples that were in the 
microarray analysis and an additional 19 three-month samples (11 from 
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patients without and eight from patients with SCR). However, we could 
not fi nd differences between patient groups with RT-QPCR as expression 
was heterogeneous and overlapping between normal and SCR patients.
As we recognised that many of the human genes involved in SCR were 
not present in the limited, immunologically oriented LDA, we performed 
a whole genome array to determine whether, with this approach, we 
could identify surrogate SCR marker genes. Since RNA isolated from 
the whole blood contains excessive amounts of globin mRNA, which 
may interfere with the microarray hybridisation 339, we performed globin 
reduction before hybridisation.
We found several differently expressed genes when we compared 
SCR with normal samples or samples taken after the clearance of SCR. 
However, the average expression fold changes were low and differences 
between samples large, suggesting that the genetic pathways contributing 
to SCR are heterogeneous. Further, because in the clinical setting SCR 
manifests itself solely in the graft, analysing whole blood samples drawn 
from peripheral veins may not fully refl ect the graft processes. After 
validation with RT-QPCR from additional samples, none of the genes 
separated SCR and normal samples due to overlapping expression 
between groups.
In one Tx study, Horwitz et al. reported using the tubes by same 
manufacturer as us in their investigation of AR-induced gene expression 
in heart Tx 340. In their study, minor fold changes of expression associate 
with AR. From their data, only one gene (Ubiquinol-cytochrome C 
reductase binding protein (UQCRB) associated with AR with over two-
fold change, which was our criterion. None of our kidney Tx patient 
samples expressed the UQCRB, and it may be distinctive to heart Tx.
In conclusion, we discovered only subtle changes in peripheral whole 
blood gene expression profi les in paediatric renal Tx patients with or 
without SCR. Although the genes of the immune system associate with 
clinically suspected rejection episodes, these were not signifi cant in our 
investigation of patients with SCR. Our relatively small series suggests 
that whole blood analysis is not able to fi nd robust gene expression 
biomarkers for SCR. Further studies in larger populations may reveal 
whether any of the genes with small changes in expression in our study 
might provide a supporting diagnostic method.
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STRATEGIES FOR THE FUTURE
As renal Tx treatment protocols have evolved to overcome the frequent 
rejection episodes of the early days of Tx, the aim of improving therapies 
currently emphasizes individualised immunotherapy to lengthen the graft 
and patient survival as well as to improve the recipient’s quality of life. 
Excessively potent immunosuppression increases the risk of infections, 
cancer and nephrotoxicity, while insuffi cient immunosuppression results 
in rejection.
One approach towards optimal immunosuppression is to regularly 
monitor biomarkers refl ecting processes leading to rejection. However, 
as every patient-graft pair is individual in immunological responses, no 
single biomarker is relevant for all. The current clinical monitoring of graft 
function is largely based on measuring serum creatinine/cystatin-c. This 
lacks sensitivity and specifi city and may result in too late recognition of 
rejection or nephrotoxicity. The frequent use of core needle biopsy is 
limited by its cost and invasive nature. Immunosuppression is monitored 
also by pharmacokinetics measuring concentration of drugs in blood 341. 
In addition functional assays can be performed - a new pharmacodynamic 
method detects cell-mediated immunity by measuring the concentration 
of ATP from whole blood CD4 cells following stimulation 342. Constant 
search and development continues to fi nd other noninvasive tools 
needed.
Currently tested monitoring sources include cells, mRNA and proteins 
in urine or peripheral blood. Two utilized strategies are to monitor 
alloimmune responses in the graft or global changes in immune responses 
of the host. Alloimmune monitoring takes place before and after Tx by 
measuring the reactivity of recipient HLA antibodies to donor cells or 
HLA antigens in beads. These antibody-based tools have been more 
successful than T cell-based tests for predicting rejection. However, the 
two strategies are successful only when an alloimmune response takes 
place also in circulation and not only in the graft. The second strategy, 
to monitor global changes in immune response, faces the problem of 
separating rejection and infection mediated immune responses from 
each other. Routinely used creatinine measurement detects mainly 
glomerular injury but less tubulointerstitial injury. Tubular markers have 
been found from urine that may separate ischemia from AR, chronic 
rejection, infection and nephrotoxicity, although not separating the 
latter from each other. This leads to the conclusion that whereas a single 
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biomarker for diagnosing any of the entities may never be found, a 
combination of many biomarkers may distinguish compartments and 
reveal the reason for injury. 
A new emerging fi eld is global analysis of different biomolecule 
classes that can be studied by proteomics, glycomics, lipidomics or 
metabolomics. However, as these scientifi c disciplines are much more 
complex than genomics, a large amount of work remains to be done 
simply to characterise the different molecules before even studying their 
performance as biomarkers. It is expected that a signifi cant number 
of potential novel biomarkers will be found. However, only a few can 
be expected to be validated in prospective studies and enter clinical 
practice. 343.
CONCLUSIONS
This research demonstrates the lack of robust polymorphisms among 
studied SNPs or biomarkers in investigated genes that could be included 
in routine analysis in a clinical laboratory. Even though weak associations 
were found, their predictive value was insuffi cient for use in clinical 
decision-making. However, as future technology advances are likely to 
make large-scale genetic tests affordable, data on several hundreds 
of genetic markers may be combined and used in personalized patient 
treatment 344.
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